Role of the pattern recognition receptors : toll-like receptor 2 and CD14 in murine pneumococcal meningitis by Echchannaoui, Hakim
Role of the pattern recognition receptors 
Toll-like receptor 2 and CD14 
in murine pneumococcal meningitis 
 
 
 
Inauguraldissertation 
zur 
Erlangung der Würde eines Doktor der Philosophie 
 
 
Vorgelegt der 
Philosophisch-Naturwissenschaftlichen Fakultät 
der Universität Basel 
 
 
von 
Hakim Echchannaoui  
aus Saint-Louis, Frankreich 
 
 
Basel, August 2004 
 
Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät 
Auf Antrag von: 
 
Professor Regine Landmann 
Professor Christoph Dehio 
Professor Guy Cornelis 
Professor Jean Pieters 
 
 
 
Basel, den 9 August 2004 
 
Professor Marcel Tanner, Dekan 
 
 
 
 
 
 
 
 
 
 
 
 1
Table of Contents 
 
General summary                             4 
General introduction                  6 
References                  17 
 
 
Section I: Toll-Like Receptor 2-Deficient Mice are Highly Susceptible to 
Streptococcus pneumoniae Meningitis because of Reduced Bacterial Clearing  
and Enhanced Inflammation                26 
 
Abstract                  27 
Introduction                  28 
Materials and Methods                30 
Results                  34 
Discussion                  49 
References                  55 
 
 
Section II: CD14 deficiency leads to early death in pneumococcal meningitis  
due to a high MIP-2, CXCR2, neutrophil transmigration and inflammation          61 
 
Abstract                  62 
Introduction                  64 
Results                  67 
Discussion                  76 
Materials and Methods                82 
References                  92 
Figures                103 
Tables                         112 
 2
          
Section III: Antibiotics Rescue C57BL/6, CD14-/- and TLR2-/-/CD14-/- Mice  
from Pneumococcal Meningitis; Adjuvant TACE Inhibitor Treatment is  
Required for TLR2-/- Mice              113 
 
Abstract                114 
Introduction                115 
Materials and Methods              118 
Results                121 
Discussion                125 
References                129 
Figures                134 
Table                         140 
 
 
Future perspectives               141 
References                148 
 
Acknowledgements               152 
Curriculum vitae               153 
 
 
 
 
 
 
 
 
 3
General summary 
 Streptococcus pneumoniae is the major pathogen causing meningitis in adults. 
Despite antimicrobial therapy and critical care medicine, mortality remains high and 
about 50% of the survivors suffer from neurological sequelae. In the present study, the 
function of the pattern recognition receptors TLR2 and CD14 in mediating host innate 
immune response towards S. pneumoniae, was investigated in a mouse model of 
pneumococcal meningitis using mice with a targeted deletion of the corresponding genes. 
The role of TLR2 and CD14 are the topics of sections I and II. Modulation of outcome in 
wt, TLR2-/- and CD14-/- mice with meningitis by antibiotic and/or with anti-inflammatory 
treatment with TNF-alpha converting enzyme (TACE) inhibitor treatment is evaluated in 
section III.  
TLR2-/- mice were found to have more severe clinical symptoms than did wt mice and 
subsequently showed earlier death during meningitis. This accelerated death was not due 
to sepsis, but rather to reduced brain bacterial clearing, followed by increased intrathecal 
inflammation. While the lack of TLR2 delayed bacterial clearance, leukocyte infiltration 
and enhanced inflammation, the lack or blockade of CD14 had no effect on bacterial 
clearance, but was associated with a stronger neutrophil recruitment into CSF, leading to 
excessive meningeal inflammation and aggravated disease after S. pneumoniae infection. 
In addition, this stronger neutrophil migration correlated with MIP-2 concentrations in 
brain and with enhanced migratory capacity of CD14-deficient PMN. In view of our 
observations, that different host effector functions were modulated by TLR2 and CD14 
during meningitis, we asked the question whether response to therapy was also 
modulated by these two pattern recognition receptors. We found, that antibiotic treatment 
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was efficient to rescue wt and CD14-/- mice, whereas in TLR2-/- strain, combination with 
TACE inhibitor was required. This study reveals the different effects mediated by TLR2 
and CD14 respectively in meningitis and illustrates the requirement and success of 
adjuvant therapy, when bacterial load is high and inflammation is strong in TLR2-/- mice.  
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General introduction 
Bacterial meningitis  
 Bacterial meningitis is a central nervous system disease, which is characterized by 
inflammation of the meninges (membranes around the brain) and affects the arachnoid 
and the subarachnoid space. The major symptoms, including headache, fever and signs of 
cerebral dysfunction ranging from confusion to coma are found in 85% of patients with 
acute bacterial meningitis [1]. Nausea, vomiting and photophobia may also appear. 
Bacterial meningitis remains a leading cause of infection-related death worldwide, with 
high mortality and morbidity [2]. About 50% of the survivors present with neurological 
sequelae [3]. A study, including 248 cases of bacterial meningitis, revealed that group B 
streptococcus was the predominant pathogen among newborns, Neisseria meningitidis 
among children 2 to 18 years old and Streptococcus pneumoniae among adults [4]. In this 
study, pneumococcal meningitis had the highest fatality rate (21%). In patients with 
pneumococcal meningitis, the high case fatality (which can reach 34%) has remained 
almost unchanged for several years despite antimicrobial therapy [5]. The diagnosis of 
bacterial meningitis requires in all cases a lumbar puncture. The fluid collected, called 
cerebrospinal fluid (CSF), is completely clear in healthy people. CSF is cloudy in patients 
with meningitis, protein concentration and leukocyte numbers are markedly increased 
(pleocytosis) and the majority of the cells are polymorphonuclear leukocytes (PMNs). In 
addition, glucose is reduced and lactate is increased in CSF [6]. Bacteria can be identified 
from CSF culture.  
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 Two distinct but related pathophysiological events are involved in acute bacterial 
meningitis, these are bacterial invasion of the subarachnoid space and the host 
inflammatory response to this infection. Bacterial meningitis usually occurs through 
several steps of bacteria-host interactions. To cause disease, the pathogen has to adhere to 
and colonize the nasopharynx, invade the intravascular space, and survive or multiply in 
the bloodstream. Bacteria then cross the blood-brain barrier (BBB) or blood-CSF barrier, 
survive and replicate in the subarachnoid space, eliciting the host inflammatory response. 
Adherence to and colonization of the mucosal epithelium of the nasopharynx is a 
prerequisite for the development of the disease. Colonization involves pneumococcal 
surface proteins which bind to carbohydrate receptors expressed by epithelial cells such 
as GalNAc(ß1-3)Gal, GalNAc(ß1-4)Gal [7]. Colonization of the nasopharynx is 
enhanced by other pneumococcal proteins such as neuraminidases, which decrease the 
viscosity of the mucus. After mucosal colonization, invasion of the intravascular space is 
facilitated by pneumococcal hyaluronidase, which degrades the extracellular matrix. To 
survive within the bloodstream, pneumococci must evade host defenses such as 
complement attack. Among all pneumococcal virulence factors known and identified, the 
capsular polysaccharide is the most important in protecting pneumococci against 
complement. In addition to the capsule, pneumococci release the pneumolysin toxin 
which also helps survival of the pathogen within the bloodstream. To invade the 
subarachnoid space, pneumococci have to cross either the BBB or the blood-CSF barrier. 
The BBB is formed by brain microvascular endothelial cells, which are maintained by 
tight junctions [8]. This barrier protects the brain from any pathogen present in blood. 
The blood-CSF barrier is located at the choroid plexus, the site where the CSF is 
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produced in adult brain. In contrast to brain endothelium, the plexus contains fenestrated 
capillaries and venules. For most meningeal pathogens, the precise site of entry into the 
CSF is not yet clear. However, several studies suggest that the brain endothelium rather 
than the choroid plexus is the primary site of pneumococcal entry into the CSF [9]. It has 
been shown that pneumococci enter into the cerebral compartment through the BBB via 
binding of their cell-wall component phosphorylcholine to platelet-activating factor 
(PAF) receptors expressed on activated cells [10] [11]. Once pneumococci enter the CSF, 
they multiply easily due to the fact that the CSF contains low levels of immunoglobulins 
and complement components, such as C3 [12] and usually no PMNs. Bacterial 
multiplication within the CSF induces the release of proinflammatory cytokines and 
chemokines, which lead to pleocytosis and therefore increased BBB permeability. 
Proinflammatory cytokines, such as TNFα, are involved in the pathophysiology of 
bacterial meningitis [13]. Chemokines are effective for PMN recruitment to inflammatory 
sites [14]. The CXC chemokine growth-related oncogene-α (GRO-α) was found in CSF 
of patients with bacterial meningitis and was shown to mediate chemotaxis in vitro [15]. 
Besides chemokines, PMN transmigration requires molecular interactions between 
receptors expressed on neutrophils and their endothelial counter-ligands.  The adhesion 
molecules, L-selectin, the ß2-integrins and intracellular adhesion molecule (ICAM)-1 
play a major role in PMN rolling, adherence and transmigration, respectively [16]. 
Indeed, CD11/CD18 was shown to be particularly important in migration of PMNs into 
CSF during pneumococcal meningitis, since inflammation was markedly attenuated by 
anti-CD18 antibody directed against ß2-integrins [17].  
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Streptococcus pneumoniae 
 Streptococcus pneumoniae, a Gram-positive encapsulated diplococcus also named 
pneumococcus, is a member of the family Lactobacillaceae. Individual cells are between 
0.5 and 1.25 µm in diameter, they occur in pairs or chains. They are facultatively 
anaerobes and non motile. When cultured on blood agar, they are alpha hemolytic. They 
lack catalase enzyme, which is necessary for the breakdown of hydrogen peroxide. 
Pneumococci are carried asymptomatically in the nasopharynx in up to 60% of the 
population and are most of the time completely harmless. However, nasopharyngeal 
colonization can lead to invasion through the mucosal layer and therefore causes serious 
infections such as pneumonia, middle-ear infections (otitis media), sinusitis and 
meningitis [18]. The reasons why invasion of pneumococci occurs in some individuals 
are still largely unknown. However, both host factors, in particular an impaired immune 
system and bacterial virulence factors play an important role in the selection of 
pneumococcal serotypes causing invasive infection. Pneumococcal meningitis can affect 
individuals of any age but is observed most frequently in very young children (younger 
than 2 years) and in elderly adults (65 years or more), where the immune system is 
compromised [19]. The most important virulence factors of S. pneumoniae are the 
polysaccharide capsule, surface proteins and toxins (figure 1). Pneumococci are 
surrounded by a polysaccharide surface coat, called capsule. The capsule is the most 
important virulence factor. Indeed, all strains isolated from infected patients are 
encapsulated [20]. Moreover, a study reported the production of a mutant isolate of S. 
pneumoniae serotype 3 lacking detectable polysaccharide capsule by Tn916 transposon-
insertion [21]. In this study, this mutant was found to have greatly reduced virulence in a 
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mouse model of pneumococcal infection. The main role of the capsule in virulence is to 
protect pneumococci against phagocytosis [22]. Based on the structures of the 
polysaccharide capsule, 90 serotypes have been identified [23]. However, only a small 
fraction of these serotypes are associated with pneumococcal infection (figure 2) [20]. 
The distribution of serotypes associated with invasive pneumococcal diseases can vary 
according to age and geographic location. For example, serotype 1 was associated with 
progressive decrease in risk throughout adulthood, whereas the risk of serotype 3 disease 
increased progressively up to seventy years. In contrast, serogroups 6, 14 and 19 were 
associated with a rapid reduction in risk beyond the first ten years [24]. In addition to age, 
it was observed that serotypes associated with higher nasopharyngeal prevalence, such as 
serotypes 19 and 23, are more common in developed countries, while invasive serotypes 
1 and 5 are more common in developing countries [24].  
 Besides the capsule, pneumococcal surface proteins are important virulence 
factors [25] [26]. They can be divided into three families: Choline-binding proteins 
(Cbps), LPXTG-anchored proteins and lipoproteins. 
Cbps are anchored to the cell wall by non-covalent interaction of their carboxy-terminal 
end with the phosphorylcholine of the pneumococcal cell wall. The Cbp family includes 
the pneumococcal surface protein A (PspA), pneumococcal surface protein C (PspC) and 
autolysin (LytA). PspA is one of the most variable proteins which is expressed by all 
clinically isolates of S. pneumoniae [27]. PspA inhibits complement activation and 
phagocytosis, thus contributing to virulence of serotype 3 S. pneumoniae strain [28]. It 
was further shown that PspA exerts its virulence function by interfering with C3b 
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deposition onto pneumococci [29] [30]. In addition, it was shown that a PspA-deficient 
strain but not a PspA-expressing strain was cleared from the blood within 6 h after 
intravenous injection in mouse [29]. In this study, the authors showed that in mice 
deficient in C3 or factor B, the PspA-deficient strain was fully virulent, suggesting that 
PspA affects the activation of the alternative pathway. PspC (also know as CbpA) is 
implicated in cell surface adhesion and plays a major role in nasopharyngeal colonization 
in rats [31] and in mouse models of colonization and pneumonia [32]. It was also shown 
to bind the C3 component of complement [33]. The serotype 3 PspC was found to bind 
the human complement regulatory protein factor H (FH) and was then named as factor H-
binding inhibitor of complement (Hic) [34]. It was recently shown that Hic protein binds 
to short consensus repeats (SCRs) 8-11 in the middle region of factor H and thus, protects 
the pneumococci from opsonophagocytosis via inhibition of spontaneous C3 activation 
[35]. The family of Cbps includes also autolysins, which are members of a group of 
enzymes that degrade the peptidoglycan backbone of bacteria. In S. pneumoniae, the 
major autolysin N-acetylmuramyl-L-alanine amidase, also know as LytA, was shown to 
be involved in virulence [36]. In this study, the authors showed that the mutagenesis of 
lytA gene in serotype 2 S. pneumoniae significantly reduced virulence of this organism 
compared to wild-type strain in a mouse intraperitoneal challenge model. An indirect 
implication of LytA involves the release of cytoplasmic virulence factors such as 
pneumolysin (Ply). 
 The second group of pneumococcal surface proteins are covalently anchored to 
the cell wall through a carboxy-terminal motif-LPXTG. This motif is recognized by a 
sortase enzyme, which links the threonine residue of the motif to the peptidoglycan of the 
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bacterial cell wall. These proteins include hyaluronidase and neuraminidase. 
Hyaluronidase disrupts the hyaluronic-acid component of mammalian tissue and 
extracellular matrix. Neuraminidase cleaves N-acetyl-neuraminic acid from cell surface 
glycans such as mucin, glycolipids and glycoproteins. However, mutagenesis of either 
hyaluronidase or neuraminidase genes did not affect the virulence of serotype 2 S. 
pneumoniae in a mouse intraperitoneal challenge model [36]. Nevertheless, the authors 
observed a significant additive attenuation in virulence when both pneumolysin and 
hyaluronidase were mutated. The importance of hyaluronidase was further shown in a 
murine pneumococcal meningitis model, where intranasal application of pneumococci 
lead to the disease only if the inoculum was combined with hyaluronidase [37]. 
 The third group of pneumococcal surface proteins is composed by lipoproteins. 
This family includes the pneumococcal surface antigen A (PsaA). Further analysis 
showed that PsaA belongs to an ATP-binding cassette (ABC)-type transporter system 
involved in manganese transport [38]. The ABC-type transport system is composed of 
three components, an extracytoplasmic protein (involved in solute binding), an integral 
membrane protein (for the transport of the solute through the cell membrane) and a 
cytoplasmic protein binding ATP. It was clearly demonstrated that mutagenesis of the 
psaA gene of serotype 2 S. pneumoniae significantly reduces its virulence in both 
intranasal and intraperitoneal challenge mouse models [39]. It was also shown that psaA 
serotype 2 mutant S. pneumoniae was highly sensitive to oxidative stress [40]. 
 Besides pneumococcal surface proteins, the toxin pneumolysin (Ply) has been 
intensively studied. Ply is a cytoplasmic enzyme which is released during autolysis 
mediated by LytA. Ply is a multifunctional toxin, characterized by its cytolytic and 
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complement activation activities [41]. Ply is know as cholesterol-dependent cytolysin 
since it binds to the host cell cytoplasmic membrane cholesterol and therefore induces the 
formation of pores which leads to cell lysis. Ply was shown to induce disruption of tissue 
barriers within the respiratory tract [42] and was found a virulence factor in both 
intranasal and intraperitoneal challenge mouse model [39]. Ply toxin play a role in the 
pathogenesis of meningitis, since it was shown that Ply-deficient serotype 2 S. 
pneumoniae strain was less virulent in a mouse meningitis model [43] and purified 
pneumolysin was an important component for damaging the BBB [44]. This toxin was 
also shown to induce neuronal apoptosis in a rabbit model of pneumococcal meningitis 
[45].  
 Among other pneumococcal components, unmethylated CpG bacterial DNA was 
also found to contribute to meningitis by causing a macrophage infiltration into the CSF 
of rats and mice [46]. Intracisternal injection of bacterial DNA induced transient 
accumulation of cytokines in CSF, which could be abolished by nitrate synthase 
inhibitors and by selectin blockade [46]. 
 
Around 1940, all strains of the bacteria pneumococcus were sensitive to the antibiotic 
penicillin. However, since a penicillin-resistant pneumococcus was first identified in the 
early 1960s [47], the incidence of penicillin-resistant S. pneumoniae strains has been 
gradually increasing. In addition to penicillin resistance, multidrug-resistant pneumococci 
have been identified during the last decade. However, a combination of vancomycin and 
a third generation of cephalosporin is recommended in areas with reported penicillin-
resistant or cephalosporin-resistant strains [48].  
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 There are currently two vaccines that protect against pneumococcal disease, a 23-
type polysaccharide vaccine for people over the age of two and a newer 7-type conjugate 
vaccine for children aged two months to two years. 
The 23-type polysaccharide vaccine, which is available since more than 20 years can 
protect most adults for five years or more against the top 23 pneumococcal 
polysaccharides causing invasive pneumococcal infection. Since non-conjugated 
polysaccharides are T-cell independent antigens, the antibody response is short and 
limited, and memory B-lymphocytes can not be generated. Thus, polysaccharide capsule 
antigens do not elicit protective levels of antibodies in children under two years of age, 
and in individuals with advanced immunological impairment. Furthermore, 
polysaccharides do not induce immunological memory, which is required for subsequent 
booster responses. The limitations of this vaccine have been overcome by conjugating the 
capsular polysaccharides to protein carriers [20]. The conjugation enhances the 
immunogenicity of pneumococcal vaccines by inducing T-cell dependent responses to 
these protein carriers. The newer 7-type conjugate vaccine (Prevnar 7) contains serotypes 
4, 6B, 9, 14, 18C, 19F and 23F conjugated to the T-dependent protein carrier, diphtheria 
CRM197 protein. Recent epidemiological studies from Germany, Denmark, Greece, the 
United Kingdom, Spain, and southern Sweden have suggested that coverage rates for this 
conjugate vaccine could range from 53% to 83% among children in these countries [49]. 
The efficacy of Prevnar 7 in preventing invasive pneumococcal disease was demonstrated 
in a study including a large number of infants, who were given the vaccine at 2, 4, 6 and 
12 to 15 months of age [50]. 
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Antibiotic therapy is applied to eradicate the bacterial pathogen; however several animal 
studies have shown that bacterial lysis, induced by antibiotic therapy, enhances CSF 
inflammation, which in turn may contribute to an unfavorable outcome [51]. The cell 
wall components which result from degradation by either antibiotic or the host immune 
system are potent chemoattractants [22] and induce synthesis of inflammatory mediators 
such as TNFα and IL-6 by human monocytes [52]. In addition to the pneumococcal cell 
wall components, the pneumolysin toxin, which is released after bacterial lysis, has been 
shown to stimulate in vitro the production of inflammatory cytokines such TNFα [53]. 
The exact mechanisms of host immune activation by pneumococcal components are not 
yet fully understood. However, it was clearly demonstrated that the cell wall component 
peptidoglycan binds to the pattern recognition receptor CD14 [54]. The transmission of 
the signal after activation of CD14 receptor occurs through another pattern recognition 
receptor containing an intracytoplasmic/signaling domain, TLR2 [55]. It is further 
known, that pneumolysin interacts with TLR4 [56] and bacterial DNA, which is released 
during bacterial autolysis activates the host via TLR9 [57]. 
To determine the function of the pattern recognition receptors TLR2 and CD14 in 
mediating host innate immune response in meningitis induced by S. pneumoniae, we 
investigated their implications in a mouse pneumococcal meningitis model using mice 
with a targeted deletion of the corresponding genes. The role of TLR2 will be discussed 
in section I and the role of CD14 in section II. In section III, we further investigated the 
outcome in wt, TLR2-/- and CD14-/- mice with meningitis under antibiotic treatment 
and/or anti-inflammatory treatment with TACE inhibitor drug. We also investigated the 
course of meningitis and the treatment response of TLR2-/-/CD14-/- mice. 
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Figure 1. Summary of the main virulence factors of S. pneumoniae strains (the 
capsule is not shown) [26]. 
 
 
 
 
 
Figure 2. Most common serogroups/types causing invasive pneumococcal disease in 
Europe and North America [24]. 
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Abstract  
 
Toll-like receptor-2 (TLR2) mediates host responses to gram-positive bacterial wall 
components. TLR2 function was investigated in a murine Streptococcus pneumoniae 
meningitis model in wild-type (wt) and TLR2-deficient (TLR2-/-) mice. TLR2-/- mice 
showed earlier time of death than wt mice (P < .02). Plasma interleukin-6 and bacterial 
numbers in blood and peripheral organs were similar in both strains. With ceftriaxone 
therapy, none of the wt, but 27% of the TLR2-/- mice died (P < .04). Beyond 3 hours after 
infection, TLR2-/- mice presented a higher bacterial loads in brain than did wt mice, as 
assessed with luciferase-tagged S. pneumoniae by means of a Xenogen-CCD (charge-
coupled device) camera. After 24 h, tumor necrosis factor activity was higher in 
cerebrospinal fluid of TLR2-/- than wt mice (P < .05) and was related to increased blood-
brain-barrier permeability (Evans blue staining, P < .02). In conclusion, the lack of TLR2 
was associated with earlier death from meningitis, which was not due to sepsis, but to 
reduced brain bacterial clearing, followed by increased intrathecal inflammation. 
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Introduction 
 
Streptococcus pneumoniae is the major cause of meningitis in adults. Despite 
antimicrobial therapy and critical care medicine, the mortality remains as high as 28% 
[1]. In addition, 50% of the survivors suffer from neurological sequelae, indicating post-
inflammatory damage [2]. In the pathogenesis of meningitis, penetration of bacteria 
through the blood-brain barrier (BBB) initiates activation of brain endothelia and leads to 
leukocyte recruitment and inflammatory mediator release. Subsequently, the 
subarachnoidal inflammation stimulates astrocytes, microglia and neurons to produce 
cytokines and chemokines [3] [4] [5]. A bacterial level of ≥ 5 log cfu and more in the 
brain initiates a harmful inflammatory cascade, which causes development of symptoms 
and determines the prognosis [6]. 
Pneumococci enter into the cerebral compartment through the BBB via binding of 
their cell-wall component phosphorylcholine to the platelet-activating factor receptors 
expressed on activated cells [7] [8]. In view of the finding that antagonists of the platelet-
activating factor receptor do not block completely bacterial invasion [7] [8], other cell-
wall components such as peptidoglycan and lipoteichoic acid, might also induce 
inflammation via activation of pattern recognition receptors expressed in these cells [9]. 
Toll was first cloned in Drosophila species [10] and was found to be involved in 
host defense against fungal infection [11]. In humans, 10 homologous genes have been 
identified encoding Toll-like receptors (TLRs) [12] [13] [14]. TLR2 is involved in cell 
activation by gram-positive bacterial cell wall and membrane components, such as 
peptidoglycan, lipoteichoic acid, and lipoproteins [15] [16] [17]. Accordingly, 
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macrophages isolated from TLR2-deficient (TLR2-/-) mice are hyporesponsive to 
Staphylococcus aureus peptidoglycan stimulation [18]. Despite growing evidence 
implicating TLR2 in recognition of gram-positive bacterial cell-wall components in vitro, 
its role in bacterial meningitis is still unknown. In this study, we compared disease 
severity and outcome in TLR2-/- and wild-type (wt) mice in an adult mouse model of S. 
pneumoniae and Listeria monocytogenes meningitis. Bacterial numbers in the brain, 
bacterial counts, and leukocyte recruitment into the subarachnoid space, as well as 
meningeal inflammation and BBB permeability, were analyzed.  
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Materials and Methods 
Preparation of bacterial inocula. S. pneumoniae (clinical isolate of serotype 
3) was grown for 7 h in double Mueller-Hinton broth (MHB) (Difco Laboratories), 
subcultured overnight in new Mueller-Hinton broth, and washed in 0.9% sterile saline 
(12,000 g for 6 min) immediately before use. The inoculum size was calculated from 
optical density determinations (optical density of 0.4 = 1 x 108 cfu) and was 
retrospectively assessed by counting colony-forming units on blood agar plates. L. 
monocytogenes (strain EGD; provided by R. M. Zinkernagel, University Hospital, 
Zürich) was grown overnight at 37°C, yielding 1-2 x 109 cfu in trypticase soy broth (BBL 
Microbiology Systems).  
Mouse meningitis models. Six- to eight-week old C57BL/6 wt (RCC) and 
TLR2-/- mice (provided by William J. Rieflin, Tularik, South San Francisco, CA; mice 
had been back-crossed for 6 generations on a C57BL/6 background) were kept under 
specific pathogen-free conditions. Mice were anesthetized via intraperitoneal injection of 
100 mg/kg ketamine (Ketalar; Warner-Lambert) and 20 mg/kg xylazinum (Xylapan; 
Graeub) and subsequently inoculated intracerebrally into the left forebrain with either 
0.9% NaCl, live S. pneumoniae (2 x 102 or 3 x 103 cfu), or L. monocytogenes (5 x 102 
cfu) in a 25 µL volume. In addition to the intracerebral inoculation, selected experiments 
were done by an intracisternal route of infection, as described elsewhere for experimental 
meningitis in infant rats [19]. Mice (n = 10 each for C57BL/6 wt and TLR2-/-) were 
deeply anesthetized and infected by direct intracisternal injection of 10 µL saline 
containing 8.5 log10 cfu/mL S. pneumoniae by means of a 32-gauge needle. 
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The health status of the mice was assessed by the following scores as described 
previously [20]: 1, exhibited normal motor activity and turned upright in <5 s when put 
on its back; 2, decreased spontaneous activity, but still turned upright in <5 s; 3, turned 
upright in >5 s; 4, did not turn upright; 5, did not move. After 6, 12, 24, 48 and 72 h or if 
they presented with a score of 5, mice were killed by intraperitoneal injection of 100 
mg/kg pentobarbital (Abbott Laboratories). Blood was obtained by intracardiac puncture 
and collected in EDTA. Animals were perfused with Ringer’s solution (Braun Medical) 
into the left cardiac ventricle until the effluent became clear. Cerebrospinal fluid (CSF) 
was obtained by puncture of the cisterna magna as described previously [21]. Because of 
the small volumes (3-6 µL) obtained from each animal, CSF from 4 mice was pooled. 
Selected mice were treated with 80 mg/kg ceftriaxone (Rocephin, Hoffmann-La 
Roche) dissolved in 0.1 mL saline via intraperitoneal injection twice daily for 5 days. 
Treatment was started 18 h after infection. For the leukocyte depletion treatment, 
cyclophosphamide (Sigma) was reconstituted with sterile PBS and injected 
intraperitoneally (250 mg/kg in 0.2 mL) 48 h before S. pneumoniae inoculation. 
 
Real-time in vivo imaging study of meningitis using bioluminescent S. 
pneumoniae transformed with Gram-positive lux transposon.    Mice were intracerebrally  
injected with 3 x 103 cfu of luciferase-tagged S. pneumoniae serotype 3 (Xen10) and 
subsequently shaved for better imaging. This bacterial strain, (provided by L. Chen; 
Xenogen) was constructed as described elsewhere [22]. After infection, analysis of 
photons was done repeatedly in mice under isoflurane inhalation anesthesia in an IVIS 
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CCD (charge-coupled device) camera (Xenogen) coupled to the LivingImage software 
package (Xenogen). 
 
Determination of bacterial counts and inflammatory parameters. Blood samples 
collected in EDTA and pooled CSF samples were serially diluted in 0.9% NaCl to assess 
the bacterial load after plating and incubation at 37°C for 24 h. Blood and CSF were 
centrifuged at 10,000 g for 20 min (4°C) and CSF was centrifuged at 800 g for 7 min 
(room temperature), to obtain plasma and cell free CSF, respectively. Thereafter, they 
were stored at -20°C until cytokine determinations were done. The pelleted CSF cells 
were counted and identified via cytospin or phenotypically analyzed. Brains were 
removed, and hemispheres were separated and homogenized with a Polytron 
homogenizer in 1 mL of  0.1 mol/L PBS. Bacterial titers were determined by plating 
serial 10-fold dilutions in 0.9% NaCl on blood agar plates. The concentration of the pro-
inflammatory cytokine tumor necrosis factor (TNF) in plasma and CSF was determined 
with a bioassay, measuring the degree of cytotoxicity on WEHI cells in the presence of 1 
µg/mL actinomycin D, with use of mouse recombinant TNF as a standard. Interleukin 
(IL)-6 in plasma was measured by a mouse IL-6 ELISA kit (OptEIA; Pharmingen). 
 
Evaluation of BBB integrity. BBB permeability was assessed by measuring 
Evans blue extravasation, according to a method described elsewhere [23]. Evans blue 
(Sigma, 0.2 mL, 2% in NaCl; Sigma) was injected into the tail vein of infected (24 or 48 
h) mice 60 min before death. Mice were perfused as described above, their brains were 
removed, and the hemispheres were separated. Each hemisphere was homogenized in 1 
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mL of 0.1 mol/L PBS and then centrifuged at 1,000 g for 15 min; 0.7 mL of 100% 
trichloroacetic acid was added to 0.7 mL of the supernatant. The mixture was incubated 
at 4°C for 18 h and then centrifuged at 1,000 g for 30 min. The amount of Evans blue in 
the supernatant was measured spectrophotometrically at 610 nm and compared with a 
serially diluted standard solution. Results were expressed as micrograms per brain 
hemisphere. 
 
Statistical analysis.  Differences in survival between wt and TLR2-/- mice were 
tested by the Kaplan-Meier analysis log-rank test. Data of disease severity scores were 
assessed by analysis of variance corrected for repeated measurements, followed by 
posthoc analysis (Fisher’s P least-squares difference, Scheffe, and Bonferroni/Dunn 
tests). Results of the colony-forming unit measurements and IL-6 levels in blood were 
compared by the Mann-Whitney U test. Differences in CSF parameters between wt and 
TLR2-/- mice were analyzed with the nonparametric Wilcoxon signed rank test. The 
relationship between 2 parameters (parametric variables) was assessed in a linear 
regression model with the Spearman rank correlation test. In all statistical tests, P < .05 
was considered to be statistically significant. 
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Results 
TLR2-/- mice have a higher susceptibility to S. pneumoniae and L. monocytogenes 
meningitis.  To evaluate the in vivo role of TLR2 during gram-positive bacterial 
meningitis, wt and TLR2-/- mice were infected intracerebrally with S. pneumoniae or L. 
monocytogenes. The severity of the disease was monitored by assessing both the clinical 
score and the survival rate.  
Control animals, injected with 0.9% NaCl, showed no altered health status. 
Infected mice remained free of clinical signs of meningitis at 6 and 12 h after infection 
but had gradually reduced spontaneous activity between 12 and 24 h (data not shown). As 
shown in figure 1A, both wt and TLR2-/- mice became severely sick during S. 
pneumoniae meningitis. The percentage of severely ill mice was significantly higher in 
TLR2-/- than control mice after 72 h (P < .02, repeated-measures analysis of variance). 
Indeed, only 30% of TLR2-/- mice survived at 72 h, and all died 102 h after infection 
(figure 1B), whereas 60% of the wt mice survived at 72 h and died of S. pneumoniae 
meningitis later (136 h after infection). TLR2-/- mice also showed reduced survival time 
(P < .02; Kaplan-Meier analysis), compared with wt mice with L. monocytogenes 
meningitis (table 1).  These results show that TLR2-/- mice had more severe symptoms 
and earlier death than did wt mice during S. pneumoniae and L. monocytogenes 
meningitis.   
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Figure 1. A, Percentage of wild-type (wt; n = 22) and Toll-like receptor-2-deficient (TLR2-
/-; n = 21) mice showing high severity score (including score 4 and score 5) after intracerebral 
injection of 2 x 102 cfu of Streptococcus pneumoniae. Data from 3 independent experiments are 
represented as the mean percentage of high severity score ± SD. ** P < .02, repeated-measures 
analysis of variance (ANOVA). B, Survival of TLR2-/- (n = 21) and wt (n = 22) mice after 
intracerebral injection of 2 x 102 cfu of S. pneumoniae. P < .02, in log-rank test. 
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Table 1. Mean survival time of Listeria meningitis in Toll-like receptor-2-deficient 
(TLR2-/-) and wild-type (wt) mice. 
      No. of   Survival time,     
Mouse strain          mice   mean h ± SD     P 
wt               11   91.5 ± 20.4  < .02a  
TLR2-/-            19   71.5 ± 16.5    _  
NOTE.  Female mice (6-8 weeks old) were infected intracerebrally with 5 x 102 
cfu of L. monocytogenes in 25 µL of NaCl. 
a  Log-rank test in Kaplan-Meier analysis. 
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Higher disease severity in TLR2-/- mice is independent of sepsis. To investigate, 
whether the high susceptibility of TLR2-/- mice to meningitis was due to impaired host 
defense, colony-forming units in blood were determined 1, 2 and 3 days after infection 
with 3 x 103 cfu of S. pneumoniae. Bacterial counts were similar in wt and TLR2-/- mice 
at all time points (figure 2A). Six and 12 h after infection, < 10% of both wt and TLR2-/- 
mice showed positive blood cultures results at low bacterial density (data not shown). 
Plasma IL-6, a prognostic marker of sepsis [24] was also analyzed during 
meningitis. In accordance with bacterial counts, IL-6 levels were not significantly 
different in wt and TLR2-/- mice 1-3 days after infection (figure 2B). Twelve and 24 h 
after intracerebral infection, emitted photons from luciferase-tagged S. pneumoniae were 
analyzed in peripheral organs (figure 3). Twenty-four hours after infection, fluorescence 
accumulated only in the lung with a similar intensity in wt and TLR2-/- mice. No other 
organ showed a detectable level of emitted photons 12 and 24 h after infection. Taken 
together, these data indicate that wt and TLR2-/- mice had a similar severity of sepsis, and 
therefore an intact systemic host defense during S. pneumoniae meningitis. 
To differentiate between sepsis and inflammation as a cause of death, wt and 
TLR2-/- mice received antibiotic treatment, to cure from sepsis. It is known that wt mice, 
treated in the first 24 h after infection with ceftriaxone (80 mg/kg every 12 h for 5 days), 
survive without apparent signs of meningitis [25]. Delay of treatment beyond 30 h leads 
to death in > 50% of the infected mice [25]. We treated infected mice with ceftriaxone 
after S. pneumoniae infection and the obtained clinical scores and survival rate of both 
ceftriaxone-treated and control mice are shown in table 2. With ceftriaxone-treatment, all 
wt mice survived without any clinical signs of disease  
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Figure 2. Colony-forming unit counts in blood (A) and interleukin (IL)-6 levels in plasma 
(B) in wild-type (wt; n = 22) and Toll-like receptor-2-deficient (TLR2-/-; n = 21) mice after 
intracerebral injection of 3 x 103 cfu of Streptococcus pneumoniae. Blood was collected 24, 48, 
and 72 h after infection. Results from individual are shown. Horizontal line, mean. P > .05, 
Mann-Whitney U test. 
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Figure 3. Emitted photons by luciferase-tagged Streptococcus pneumoniae in several 
organs from wild-type (wt) and Toll-like receptor-2-deficient (TLR2-/-) mice detected by a highly 
sensitive CCD (charged-coupled device) camera (IVIS imaging system; Xenogen) 12 and 24 h 
after intracerebral injection of 3 x 103 cfu of Streptococcus pneumoniae. Results from 1 wt and 1 
TLR2-/- mouse are shown. Kd, kidney; Lg, Lung; Lv, liver; Sp, spleen; Th, thymus. 
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after 6 days, whereas 4 (27%) of 15 TLR2-/- mice died despite treatment (P < .04, 
Kaplan-Meier analysis). As described above, all untreated wt and TLR2-/- mice died 
within 4-6 days (data not shown). Treatment failure in TLR2-/- mice could be explained 
by the fact that at the initiation of the treatment (18 h after infection), 7% of TLR2-/- mice 
but none of the wt mice were severely sick. By day 6, 27% of the treated TLR2-/- mice 
remained severely ill and subsequently died, whereas all wt mice recovered during 
treatment.  
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Table 2. Effect of ceftriaxone treatment on survival during Streptococcus 
pneumoniae meningitis in wild-type (wt) and Toll-like receptor-2-deficient (TLR2-/-) 
mice. 
 
Mouse strain, 
days after infection 
No. (%) of 
mice showing 
severe lethargy 
 
 
Survivors, % 
wt (n = 15) 
   1 
   2 
   3 
   4 
   6 
TLR2-/- (n = 15) 
   1 
   2 
   3 
   4 
   6 
 
0 
1 (7) 
1 (7) 
1 (7) 
0 
 
1 (7) 
3 (20) 
3 (20) 
4 (27) 
4 (27) 
 
100 
100 
100 
100 
100 
 
100 
100 
100 
87 
73 
 NOTE.  Ceftriaxone treatment (80 mg/kg) was administered intraperitoneally every 12 h 
during 5 days, starting 18 h after intracerebral injection of 3 x 103 cfu of S. pneumoniae. P < .04, 
TLR2-/- vs. wt mice (log-rank test in Kaplan-Meier analysis). 
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TLR2-/- mice have a higher bacterial load in brain and stronger meningeal 
inflammation after intracerebral infection with S. pneumoniae than do wt mice. 
To further explain the high susceptibility of TLR2-/- mice to S. pneumoniae meningitis, 
we examined bacterial counts, leukocyte recruitment, and TNF release in the CSF as well 
as bacterial densities in the brain. Monitoring of meningitis in animals intracerebrally 
injected with luciferase-tagged S. pneumoniae revealed a higher fluorescence intensity in 
TLR2-/- brains than in wt brains between 2 and 24 h after infection (Figure 4A). Twenty-
four hours after infection, mice were killed, and the photon emission was stronger and 
more widely spread in isolated brains of TLR2-/- mice than in those of wt mice (figure 
4A). In particular, signals from bacteria were differently distributed in TLR2-/- and wt 
mice. In contrast to the picture in wt mice, bacteria were not accumulated in the 
ventricles of TLR2-/- mice but concentrated on the ipsilateral and contralateral side of the 
injection site. Furthermore, a quantitative time course analysis of emitted fluorescence 
from infected animals showed a more rapid bacterial growth in TLR2-/- mice, compared 
with wt mice, which was most pronounced already 2 h after S. pneumoniae inoculation 
(figure 4B). Counting of colony-forming units in ipsilateral and contralateral brain 
hemispheres 24 h after infection of the left side of the brain confirmed that, in both parts, 
bacterial numbers were higher in TLR2-/- than wt mice (median, 1.8 x 107 cfu [left] and 
1.2 x 107 cfu [right] in TLR2-/- mice, 7.4 x 105 cfu [left] and 8.8 x 105 cfu [right] in wt 
mice; P < .04). Counting of colony-forming units in brain homogenates 24 h after 
intracisternal infection with S. pneumoniae confirmed, that bacterial numbers were also 
significantly higher in TLR2-/- than wt mice when the intracisternal route of infection was 
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Figure 4.  A, Time course of infection in wild-type (wt) and Toll-like receptor-2-deficient 
(TLR2-/-) mice after intracerebral injection of 3 x 103 cfu of luciferase-tagged Streptococcus 
pneumoniae. Images from 1 animal in each group at time of infection (0 h) and 2, 4, 6, 12, and 24 
h after infection and isolated brains 24 h after infection are shown. B, Emitted light was also 
quantified by LivingImage software (Xenogen) and shown as bacterial growth gradient 
(calculated as ratio between emitted photons and time elapsed after infection). Results from 
individual mice are shown, with median (horizontal line). ** P < .0001, repeated-measures 
analysis of variance (ANOVA) (n = 11 and n = 10 at 2 and 4 h, n = 10 and n = 9 at 6 and 12 h, n 
= 6 and n = 5 at 24 h, for wt and TLR2-/- mice, respectively). 
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used (median, 6.2 x 105 cfu and 6.8 x 104 cfu in TLR2-/- and wt mice, respectively; P < 
.04, Mann-Whitney U test). 
Twelve hours after intracerebral infection, TLR2-/- mice showed a lower influx of 
leukocytes, compared with wt mice (mean ± SD, 1703 ± 186 and 12,110 ± 3691 
leukocytes/µL of CSF, respectively; P < .05; figure 5A). After this time point, leukocyte 
numbers and bacterial counts in the CSF of the 2 groups were almost identical (figure 
5B). As expected, infiltrating polymorphonuclear cell numbers and bacterial counts in the 
CSF were similar in TLR2-/- and wt mice after intracisternal infection as we had observed 
in the intracerebral infection model. 
Meningeal inflammation, as assessed by TNF activity in the CSF, was 
significantly higher in TLR2-/- than in wt mice 24 h after infection with S. pneumoniae 
(1077 ± 201 and 705 ± 74 pg/mL of CSF, respectively; P < .05; figure 5C). Early after 
infection, at 6 and 12 h, TNF activity was low or below detection (< 20 pg/mL), and, 
after 48 h, the difference between TLR2-/- mice and wt mice was no longer statistically 
significant, because of high variability (figure 5C). 
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Figure 5. Time course of cerebrospinal fluid (CSF) parameters in wild-type (wt) and Toll-
like receptor-2-deficient (TLR2-/-) mice (n = 12 at each time point in both groups) after 
intracerebral injection of 3 x 103 cfu of Streptococcus pneumoniae. Pooled CSF from 4 mice was 
collected at indicated times after infection. Infiltrating leukocytes (A), bacterial numbers (B), and 
tumor necrosis factor (TNF) levels (C) were analyzed in CSF. Results of 3 independent 
experiments are shown as mean ± SD. When errors bars are not seen, they fall within the symbol. 
* P < .05 and ** P < .02, both by the Wilcoxon signed rank test. 
B
0
1
2
3
4
5
6
7A 6 
5 
* 
* P < .05  4 
(Wilcoxon signed 
rank test) 
0 12 24 36 48 60 72
wt 
TLR2-/-
2 
3 wt
TLR2-/-
0 12 24 36 48 60 72
Hours after infection Hours after infection
TNF, pg/mL of CSF 
C 1400 **
1200 
wt 
Hours after infection
0 
200 
400 
600 
800 
1000 
TLR2-/-
** P < .02  
(Wilcoxon signed 
rank test)  
6 24 4812 
 45
An association between disease severity and meningeal inflammation was 
documented by a significant relationship between TNF activity in the CSF and severity 
score 24 h after infection (r = 0.589; P < .001; data not shown). Thus, the level of TNF in 
CSF might reflect the intensity of clinical signs during the first day of infection.  
   To investigate whether infiltrating leukocytes contribute to meningeal 
inflammation during S. pneumoniae meningitis, we analyzed TNF activity in the CSF in 
infected mice rendered leukopenic by cyclophosphamide. As shown in figure 6, TNF 
activity was significantly decreased in leukopenic TLR2-/- mice, compared with 
immunocompetent mice 24 h after infection (P < .05). In contrast, no difference in TNF 
activity was observed in wt mice with or without cyclophosphamide pretreatment.  
 
TNF, pg/mL of CSF
 
Figure 6. Tumor necrosis factor (TNF) levels in cerebrospinal fluid (CSF) in leukocyte-
depleted and immunocompetent control animals after intracerebral injection of 3 x 103 cfu of 
Streptococcus pneumoniae. In each experiment, pooled CSF from 4 mice was collected 24 h after 
infection. Results of 3 independent experiments are shown as mean ± SD. ** P < .05, 
nonparametric Wilcoxon signed rank test. Leukocyte depletion in CSF was 81.2 ± 20.1% in Toll-
like receptor-2-deficient (TLR2-/-) mice and 76.2 ± 10.5% in wild-type (wt) mice. 
0 
200 
400 
600 
800 
1000 
1200 ** P < .05 (Wilcoxon signed rank test)  
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TLR2-/- mice have enhanced blood-brain barrier permeability after i.c. infection 
with S. pneumoniae. Alteration of the BBB is a consequence of meningeal 
inflammation. Therefore, we analyzed changes in BBB permeability during S. 
pneumoniae meningitis with the Evans blue extravasation method. 
   Measures of BBB permeability and severity of the disease in wt and TLR2-/- mice 
are presented in table 3. Infection with S. pneumoniae induced alteration of the BBB in 
both wt and TLR2-/- mice, as evidenced by higher Evans blue concentrations in brains of 
TLR2-/- mice, compared with control mice. This BBB disruption occurred early in disease 
(24 h) and was stronger in TLR2-/- mice than in wt mice. At the same time, TLR2-/- mice 
showed more severe symptoms of meningitis than did wt mice (table 3). In addition, 
meningeal inflammation, assessed by TNF in the CSF, was significantly related to BBB 
permeability (r = 0.768; P < .02; data not shown). 
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Table 3. Blood-brain barrier permeability and clinical score in Toll-like receptor-2-
deficient (TLR2-/-) and wild-type (wt) mice after intracerebral injection of 3 x 103 cfu of 
Streptococcus pneumoniae. 
 24 h  48 h  
Mouse 
strain 
Clinical 
scorea
Evans 
blue stainb
Clinical 
scorea
Evans 
blue stainb
wt 
TLR2-/-
1.3 (1-2.8) 
1.9 (1-3) 
1.1 ± 0.1 
1.3 ± 0.6 
3.5 (3-4) 
4.9 (4.8-5) 
3.4 ± 1.9 
7.0 ± 0.9 
a Data are median (range) clinical score. See Materials and Methods for the scoring 
system. 
b Data are mean ± SD fold increase, compared with uninfected control mice. 
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Discussion 
We have studied the in vivo role of TLR2 in an adult mouse model of S. pneumoniae 
meningitis. TLR2-/- mice had more severe clinical symptoms than did wt mice and 
subsequently showed earlier death. Similar results were obtained with L. monocytogenes 
as the infecting agent (table 1). This result is in agreement with a previous report on 
increased mortality of TLR2-/- mice from S. aureus sepsis [26]. In that model, TLR2-/- 
mice showed reduced systemic bacterial clearance in comparison to wt mice after a high 
but not after a low intravenous inoculum. According to the authors, this was due to 
failure to recognize invading bacteria [26]. Instead, in our model with a low inoculum in 
the brain, systemic host defense was not impaired in the absence of TLR2, because 
similar plasma levels of IL-6 and numbers of bacteria were observed in blood and organs 
of TLR2-/- and wt mice. Moreover, in ceftriaxone-injected animals, in which the infection 
is successfully treated, 27% of the TLR2-/- mice died, whereas all wt mice survived. This 
indicates that the higher mortality in TLR2-/- mice was not due to defective bacterial 
clearance in the periphery.  
  We observed more bacteria in the brains, but not in the CSF, of TLR2-/- mice. 
More rapid growth, which was detectable as early as 2 h after infection, was associated 
with a protracted accumulation of the bacteria around the site of injection in TLR2-/- 
mice. This was in contrast to wt mice, in which the bacteria were mainly in the ventricles 
after 24 h. It is known that TLR2 is constitutively expressed in the choroid plexus and the 
lateral ventricle lining [27]. It can be hypothetized that the lack of TLR2 in the choroidal 
epithelia and/or endothelia and in the ependymal cells contributed to the particular 
distribution pattern of the bacteria, by altering the CSF flow. The different localization of 
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the bacteria in brains of wt and TLR2-/- mice probably also explains why the number of 
colony-forming units in CSF were similar in both strains.  
  Leukocyte infiltration following bacterial invasion into the central nervous system 
is correlated with brain edema and injury in bacterial meningitis [28] [29]. The rapid 
increased bacterial growth in brain homogenates of TLR2-/- mice may, in turn, have 
contributed to the enhanced inflammation and to the earlier aggravation of the symptoms 
in these animals. Despite higher bacterial numbers in brain, pleocytosis was not 
significantly different in wt and TLR2-/- mice, except for a transient delay in leukocyte 
recruitment 12 h after infection in TLR2-/- mice. Perhaps the delayed leukocyte influx 
into the CSF could be explained by a lack of TLR2 action on integrin or intercellular 
adhesion molecule (ICAM) expression, because it has been shown, that blocking of the 
integrin CD18 and of the adhesion molecule ICAM attenuated meningeal inflammation 
and tissue damage [30] [31]. However, it is also possible that the recruitment of 
leukocytes may have been delayed in TLR2-/- mice because of the lacking TLR2 activity 
on IL-8 [32]. Indeed, a previous study showed that intravenous treatment with antibody 
against IL-8 attenuates the neutrophil pleocytosis during experimental pneumococcal 
meningitis [33]. 
Despite the slower early influx of leukocytes, we observed higher TNF activity during S. 
pneumoniae meningitis in the CSF of TLR2-/- than of wt mice. TNF is elevated in CSF in 
human and experimental meningitis. It has detrimental effects, since its neutralization 
decreases meningeal inflammation as shown in a rabbit pneumococcal meningitis model 
[34] [35]. However, the total lack of TNF also adversely effects host defense in 
meningitis. Indeed, mice with a targeted deletion of TNF die earlier than controls from 
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intracerebral S. pneumoniae infection because of the lack of systemic clearance of 
bacteria [36]. A systemic protective effect of TNF in our model is unlikely, in view of 
similar signs of sepsis in TLR2-/- and wt mice. An important finding of the present study 
is that, paradoxically, TLR2-/- mice show an increased inflammation after infection. Thus, 
it appears that these animals are characterised by inefficient regulation of the 
inflammatory reaction. Because TLR2-/- mice had more TNF activity in the CSF than did 
wt mice, it is tempting to speculate that the engagement of TLR2 contributes to a 
downregulation of the TNF in the CSF. This is not ascribed to an increased production of 
IL-10 (data not shown) and might be associated with an altered release of TNF from 
intracellular stores and cell surface.  
The consequence of meningeal inflammation is an alteration of the BBB integrity. In the 
present study, the BBB disruption was markedly increased in TLR2-/- mice as compared 
to control mice, and was related to TNF levels in the CSF. This corroborates the known 
role of TNF in BBB disruption and consequently in the course of disease [35] [37] [38]. 
Our observation of a stronger in vivo TNF induction in TLR2-/- than in wt mice is in 
contrast to the reduced in vitro TNF production of TLR2-/- in macrophages in response to 
S. aureus [26]. However, an important difference in our experimental model is the use of 
live bacteria, whereas that study [26] was conducted with heat-killed bacteria. We 
therefore conclude that live S. pneumoniae and their turnover products induce TNF 
differently than do heat-killed bacteria. It is likely that, during infection, other receptors 
are activated together with TLR2. The nature of these other receptors is not clear. They 
could be other TLRs, such as TLR1 and TLR6, which are also triggered by bacterial 
products [39]. In this case, their stimulation led the release of large amounts of TNF, 
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which are higher that those induced in the presence of TLR2. This might occur because 
these TLRs show sequence similarities in their intracytoplasmic regions, and then share 
common transducing mechanisms. Other receptors involved in this signaling could be 
specific for S. pneumoniae products, such as platelet-activating factor receptors [7] or C-
reactive protein [40]. Finally, another possibility is that triggering of TLR2 on a 
particular cell type only might lead to the regulation of TNF. However, in this case it is 
not clear how the engagement of TLR2 would down-regulate the TNF release. 
  The same accelerated death rate as for those infected with S. pneumoniae was also 
observed in Listeria-infected TLR2-/- mice, yet they and Listeria-infected wt mice had 
similar TNF activity in the CSF than Listeria-infected wt mice (data not shown). This 
suggests that different mechanisms are involved in S. pneumoniae and L. monocytogenes 
meningitis.  
As reported elswhere, in L. monocytogenes meningitis, monocytes contributed to the 
leukocyte infiltration in CSF, whereas S. pneumoniae meningitis caused only 
polymorphonuclear leukocyte accumulation [41]. Together with our recent observation 
that TLR2 protein is constitutively expressed in mouse polymorphonuclear leukocyte, but 
not in macrophages (authors’ unpublished data), the excess TNF in S. pneumoniae 
meningitis may be polymorphonuclear leukocyte-derived.  To confirm this hypothesis, 
we investigated which cells contributed to the TNF release in the subarachnoid space 
during S. pneumoniae meningitis. Depletion of leukocytes by cyclophosphamide 
treatment before infection led to a decrease in TNF level in TLR2-/- but not in wt mice. 
This validated that leukocytes participated in TNF production, but were not the only 
source of TNF in TLR2-/- mice. Brain microvascular endothelia have been shown to 
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produce TNF in pneumococcal meningitis or after stimulation with cell walls of S. 
pneumoniae [7] [42]. Furthermore, we and others could show that primary cultures of 
astrocytes, microglial cells, and neurons release TNF after stimulation with live S. 
pneumoniae (authors’ unpublished data) and pneumococcal cell wall components [43]. 
In conclusion, the mouse S. pneumoniae meningitis model described here is fatal for both 
wt and TLR2-/- mice. The clinical course of meningitis, the number of bacteria, the level 
of meningeal inflammation, and BBB damage are aggravated in mice lacking TLR2. 
Taken together, these results indicate, for the first time, a contribution of TLR2 in 
regulation of bacterial clearing and inflammatory response in pneumococcal meningitis. 
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Abstract  
 
CD14 is a myeloid receptor for the bacterial cell membrane/wall components LPS and 
LTA, and associates with TLR4 and TLR2 respectively to mediate signal transduction. Its 
role in infection with live Gram-positive bacteria is controversial. Therefore, the effect of 
CD14 deficiency and blockade was studied in murine pneumococcal meningitis. 103 
colony forming units (CFU) of S. pneumoniae serotype 3 were inoculated 
subarachnoidally and mice were followed from 6 h to 5 days. CD14-/- mice and mice 
pretreated intravenously with 5 mg/kg neutralizing rat anti-CD14 antibodies showed 
higher disease severity and died earlier (P < .02) than C57BL/6 wild type (wt) mice with 
or without control antibody treatment. Early leukocyte immigration into the cerebrospinal 
fluid (CSF) was more pronounced P <.05) in CD14-/- and wt mice with anti-CD14-
treatment than in wt mice without antibody. This was not due to altered adherence 
molecule expression in either blood or CSF polymorphonuclear leukocytes (PMN) or in 
brain endothelial cells. MIP-2 and KC were similarly induced in CSF in both mouse 
strains, but MIP-2 release in brain in vivo and in endothelial cells infected in vitro was 
higher in CD14-/- than in wt mice. CD14-deficient PMN showed stronger in vitro 
chemotaxis than wt PMN towards CSF from either wt or CD14-/- injected mice, 
pneumococcal cell walls (PCW) and recombinant MIP-2. In vivo blood leukocyte 
depletion prevented leukocyte infiltration into the CSF from wt but not from CD14-/- 
mice. The larger leukocyte numbers in CSF of CD14-/- mice were responsible for a 
stronger TNF transcription and release from infiltrating cells. They were not able to 
improve bacterial clearance, since CD14-/- and wt mice showed similar CFU in CSF. TNF 
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was related to the severity score (P < .05) and thus most likely responsible for earlier 
death. In conclusion, CD14 has a protective effect in pneumococcal meningitis by 
slowing PMN migration.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 63
1. Introduction 
 
Streptococcus pneumoniae is the major pathogen causing meningitis in adults. Despite 
antimicrobial therapy and critical care medicine, mortality remains high. Up to 30% of 
patients die [1] and about 50% of the survivors suffer from neurological sequelae [2]. In 
the pathogenesis of meningitis, penetration of bacteria through the blood-brain (BBB) or 
blood-CSF barrier initiates activation of brain endothelia and glia and leads to leukocyte 
recruitment and inflammatory mediator release. Pneumococcal cell wall (PCW) 
components such as peptidoglycan (PGN) and lipoteichoic acid (LTA) may induce 
harmful inflammation via activation of pattern recognition receptors expressed in 
infiltrating and resident brain cells. 
CD14 was initially described as a receptor for lipopolysaccharide (LPS), the major 
component of the outer membrane of Gram-negative bacteria [3]. Later, CD14 has been 
shown to bind Gram-positive [4] [5] [6] or mycobacterial [7] cell wall components. It 
was therefore postulated that CD14 functions as a pattern recognition receptor of the 
innate immune system [7]. CD14 is a 55-kDa glycosylphosphatidylinositol (GPI)-
anchored glycoprotein expressed mainly in monocytes and macrophages, but also at low 
levels in neutrophils [8]. A single mRNA transcript is translated and processed in the 
endoplasmatic reticulum, where a GPI anchor is attached. As a GPI-linked protein 
without transmembrane and intracytoplasmic domains, mCD14 most likely does not 
transmit a signal on its own. It was therefore postulated that in presence of Gram-positive 
bacteria, CD14-TLR2 complexes may function to initiate signal transduction, since 
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cellular response to heat-killed Staphylococcus aureus  and S. pneumoniae [9] or purified 
LTA [10] have been shown to be mediated by CD14 and TLR2. 
In addition to membrane bound CD14 (mCD14), two soluble isoforms of CD14 
(sCD14) are generated. A 55-kDa isoform is liberated by escaping from GPI anchoring 
and the 49-kDa isoform is derived from the cell membrane by proteolytic cleavage 
through a serine protease. Soluble CD14 can mediate activation of cells that lack mCD14 
expression, such as human endothelial, epithelial and smooth-muscle cells [11] [12] [13]. 
This suggests that sCD14 binds a transmembrane receptor, although it has not been 
shown that sCD14 binds TLR2 and thereby transmits signal in the same way as mCD14 
does. Some studies reported elevated levels of sCD14 in human cerebrospinal fluid (CSF) 
during neuroinflammatory diseases, such as bacterial meningitis [14] [15]. This 
observation was also confirmed in a mouse model of experimental bacterial meningitis 
[14].  
CD14 is known to be crucial in endotoxin-induced shock as shown by the 
resistance of CD14-deficient mice to septic shock induced by i.v. or i.p. injection of 
Escherichia coli or LPS [16]. Opposed to that finding, several in vivo studies have shown 
a deleterious effect of CD14 blockade in mice or rabbits injected with Klebsiella 
pneumoniae, E. coli or Shigella flexneri [17] [18] [19]. To date, only one in vivo study 
has investigated the function of CD14 in a Gram-positive sepsis model. In that study, 
survival as well as bacterial load in lymphoid organs were similar in CD14-deficient 
(CD14-/-) and wild-type (wt) mice after i.v. infection with S. aureus [20]. Despite 
growing evidence implicating CD14 in recognition of Gram-positive bacterial cell wall 
components in vitro, its pathophysiologic role in Gram-positive bacterial infection is still 
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unknown. We therefore, investigated the in vivo role of CD14 in the pathogenesis of 
pneumococcal meningitis. 
To that aim, disease severity and outcome in mice with a targeted deletion of the 
CD14 gene and in wt mice treated with neutralizing anti-CD14 specific antibody was 
compared to wt mice following subarachnoidal infection with S. pneumoniae. Bacterial 
numbers in brain and bloodstream, bacterial counts and leukocyte recruitment into the 
subarachnoid space, as well as meningeal inflammation were analyzed. 
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2. Results 
 
2.1 CD14-/- mice show earlier death during pneumococcal meningitis 
To investigate the in vivo function of CD14 during Gram-positive bacterial 
meningitis, wt and CD14-/- mice were subarachnoidally infected with S. pneumoniae. The 
severity of disease was assessed by clinical score and survival rate. 
S. pneumoniae meningitis gradually induced lethargy in both wt and CD14-/- mice, but 
the percentage of severely sick mice was significantly higher among CD14-/- than among 
wt mice from 48 h after infection and this difference was maintained during the whole 
observation period of the disease (data not shown). The higher severity of disease 
observed in CD14-/- mice was followed by an earlier mortality in these mice. Indeed, the 
median survival time was 84 h in CD14-/- mice and 122 h in wt mice (figure 1A). 
Moreover, in vivo blockade of CD14 significantly accelerated the mortality after S. 
pneumoniae infection. Indeed, animals treated with anti-CD14 mAb (4C1) showed 
significantly earlier death as compared to animals receiving isotype-matched control 
mAb (fFigure 1B). Since the levels of soluble CD14 were similarly increased in CSF 
(3627.5 ± 1862.6 vs 3209.0 ± 3540.4 ng/mL in anti-CD14 vs isotype control treated 
mice, respectively) and serum (170.3 ± 215.7 vs 44.1 ± 41.8 ng/mL in anti-CD14 vs 
isotype control treated mice, respectively) of mice, which were treated with either anti-
CD14 or isotype control mAb, a role of sCD14 can be excluded. These results indicate 
that CD14 is directly implicated in the host response to pneumococcal meningitis. 
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2.2 CD14 deficiency does not play a role in early bacterial clearance and sepsis  
Accelerated death in CD14-/- mice could be due to earlier sepsis or enhanced 
inflammation in the brain. To test whether sepsis explained earlier death, we assessed 
bacterial load in blood and CSF of S. pneumoniae infected mice. Colony-forming units 
(CFU) in blood were detected only 24 h after infection, and were not significantly 
different in CD14-/- and wt mice (table I). In addition, CFU in CSF were also similar in 
CD14-/- and wt mice, 6, 12 and 24 h after infection (table I). Furthermore, brain bacterial 
load, which mirrors bacteria adherent to or taken up by infiltrating and resident cells, was 
followed by quantitative analysis of emitted fluorescence in a coupled-charged digital 
(CCD) camera in luciferase-tagged S. pneumoniae infected animals in vivo (figure 2A). 
Bacterial load was similar in both strains in the early hours of infection, but was higher in 
CD14-/- mice than wt mice after 24 h (figure 2B). CFU determination in brain 
homogenates, which were harvested 24 h after infection, confirmed that at 24 h after 
infection brain bacterial numbers were higher in CD14-/- than wt mice (figure 2B). Taken 
together, these data suggest that CD14 does not affect early bacterial clearance and 
development of sepsis during meningitis, but that it modulates brain bacterial load after 
24 h of infection. 
 
2.3 CD14-/- mice show a stronger leukocyte infiltration in CSF 
To further understand earlier death of CD14-/- mice during S. pneumoniae 
meningitis, we analysed leukocyte recruitment into CSF. CD14-/- mice showed a two fold 
stronger infiltration of PMN in CSF than wt mice 6 and 12 h after infection (figure 3A), 
without an alteration of subpopulation distribution. However, PMN numbers were similar 
in both mouse strains 24 h after infection (figure 3A). We then investigated, whether this 
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stronger neutrophil infiltration was induced by live S. pneumoniae and its cell wall 
components. We therefore monitored CSF pleocytosis in mice subarachnoidally injected 
with PCW. Interestingly in both mouse strains, leukocyte numbers in CSF were 10-fold 
higher 6 h after injection of PCW than after infection with S. pneumoniae, yet values in 
CD14-/- mice were again significantly higher than those in wt mice (figure 3B). This 
suggested that the stronger neutrophil influx in CSF of CD14-/- mice was not dependent 
on phagocytosis of S. pneumoniae, but was rather induced by pino- or endocytosis of 
small molecules. Importantly, leukocyte influx was the only consequence of PCW 
injection, neither clinical signs nor TNF were induced by the bacterial preparation (data 
not shown). To further characterise the in vivo role of CD14 in CSF pleocytosis, we 
analysed CSF neutrophil infiltration in mice treated with anti-CD14 mAb. Mice injected 
with anti-CD14 at the time of infection, showed a higher CSF infiltration (3.26 x 104 ± 
1.0 x 104) 12 h after infection than infected animals which received isotype-matched 
control Ab (1.53 x 104 ± 3.5 x 103). Indeed, anti-CD14 was detectable on the surface of 
PMN in the CSF of mice, which had been treated with the specific antibody, but not in 
those treated with the control antibody (data not shown). Together, these results indicate 
that either the lack or blockade of CD14 allowed enhanced neutrophil immigration in 
CSF of infected mice or of mice stimulated with bacterial components. 
 
2.4 The lack of CD14 does not alter adherence molecule expression, but leads to 
increased MIP-2 levels  
We then investigated, whether the higher leukocyte numbers in CD14-/- mice were 
due to an alteration of leukocytes or of brain endothelial cells. We analysed expression of 
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the leukocyte adherence molecules CD11a/CD18 (LFA-1), CD11b/CD18 (Mac-1), 
CD11c/CD18 (gp150, 95) and CD54 (ICAM-1) in CSF cells. All adherence molecules 
tested were similarly expressed in CD14-/- and wt mice, 6, 12 and 24 h after infection 
(data not shown). CD11c/CD18 and CD54 were weakly expressed in PMN, with mean 
fluorescence intensities (MFI) of 10 and 17 respectively. CD11a/CD18 showed MFI of 
286.8 and 277.4 for CD14-/- and wt mice, respectively and CD11b/CD18 increased to the 
same extent in CD14-/- and wt mice (MFI 1577 and 1367 respectively) 24 h after 
infection.  
Moreover, expression of leukocyte adherence molecule CD11a/CD18, 
CD11b/CD18, CD11c/CD18, CD31 (PECAM-1), CD54 and CD62-L (L-Selectin) was 
similar in peripheral blood PMN of CD14-/- and wt mice (data not shown). This indicates 
that the penetration of leukocytes through the blood-brain barrier (BBB) or the plexus 
was not facilitated by leukocyte adherence molecules and suggests an alteration of the 
endothelium in CD14-/- mice. Therefore, brain endothelia were stained by 
immunohistochemistry with antibodies against CD54, CD106 (VCAM-1) and CD62-E 
(E-Selectin). CD54 and CD106 were equally expressed in plexus choroideus epithelia of 
CD14-/- mice and wt mice 6 and 12 h after S. pneumoniae infection (data not shown). At 
the early time points these molecules were not found to be upregulated in endothelium. 
Yet later after pneumococcal infection (24 and 48 h), they were equally expressed in 
brain endothelium of both mouse strains. Moreover, immunohistochemical analysis of 
brain endothelium of mice treated with anti-CD14 mAb revealed similar CD54 
expression as isotype-control Ab injected mice 12 h after infection, despite a stronger 
CSF infiltration of neutrophils (data not shown). Taken together, these data indicated that 
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the early CSF leukocyte influx observed in CD14-/- was not due to an alteration of 
adherence molecule expression in leukocytes or brain endothelial cells.  
Alternatively, neutrophil migration from blood into the subarachnoid space could 
be affected due to increased chemokine levels in CSF. We therefore measured the 
neutrophil chemoattractants macrophage inflammatory protein (MIP)-2 and keratinocyte-
derived chemokine (KC). MIP-2 and KC levels in CSF increased between 6 and 12 h 
after S. pneumoniae infection and were found to be higher in CD14-/- mice. However the 
differences in cytokine levels were not statistically significant (table II). Soluble 
intercellular adhesion molecule (ICAM)-1, which could also play a role in neutrophil 
transmigration [21], also showed similar levels in CD14-/- and wt mice 6 and 12 h after 
infection (table II). For IL-8, the human homologue of MIP-2, a strong association with 
PMN was shown to occur [22]. Furthermore, microglial cells, astrocytes and endothelial 
cells are all known to be a source of chemokines during inflammation or after bacterial 
infection [23] [24] [25]. Therefore, MIP-2 was also measured in brain lysates, which 
contain adherent PMN and resident cells. MIP-2 was significantly higher in brains of 
CD14-/- than of wt mice (figure 4A). To address a potential role of endothelial cells 
during pneumococcal infection, we performed in vitro experiments with brain-derived 
microvascular endothelial cells (MVECs). Monolayers of MVECs from both genotypes 
of mice were infected with live S. pneumoniae at two different MOI (2 and 20) and MIP-
2 levels in the culture supernatant determined 8 and 24 h later. Higher MIP-2 levels were 
found in CD14-/- MVEC supernatants at both time points and irrespective of the MOI 
used (figure 4B). Similar results were found with the other neutrophil chemoattractants 
KC (data not shown). 
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In summary, brain-derived chemokines, but not altered adherence molecules might be the 
origin of enhanced leukocyte migration in CD14-/- mice. 
 
2.5 CSF of PCW injected mice and PCW induce a stronger chemotactic activity 
towards PMN from CD14-/- mice 
CSF of patients with bacterial meningitis is known to induce chemotactic activity 
in human PMN in vitro [26]. We therefore tested, whether CSF from infected CD14-/- and 
wt mice differed in the chemotactic activity towards mouse blood PMN in vitro. CSF 
from infected CD14-/- and wt mice had similar chemotactic activity, since the origin of 
CSF did not influence the migration capacity of PMN cells of either mouse strain (data 
not shown). However the percentage of PMN, which migrated towards CSF was 
significantly higher if cells were derived from CD14-/- than from wt mice (figure 5A). To 
assess the effect of chemokines in the CSF on PMN, chemotaxis was performed with 
CSF which was pretreated with either neutralizing anti-MIP-2 alone or combined with 
anti-KC mAb. For this migration assay, PMN from CD14-/- mice were selected because 
of a higher percentage of migrated cells. As shown in figure 5A, preincubation of CSF 
with anti-MIP-2 mAb did not reduce the number of migrated PMN as compared to CSF 
preincubated with control rat IgG. Similar results were observed with neutralization of 
both MIP-2 and KC (data not shown). This was expected since MIP-2 and KC levels did 
not significantly differ in CSF from CD14-/- and wt mice. A stronger migration was also 
observed with PMN from CD14-/- than wt mice when a low dose of PCW (30 ng) was 
used as chemoattractant instead of infected CSF (figure 5A). This difference between 
CD14-/- and wt PMN cells was abolished when a high dose of PCW (3 µg) was applied 
(data not shown). Interestingly however, PMN from CD14-/- mice also migrated more 
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strongly towards rMIP-2 and this effect was neutralized by anti-MIP-2 mAb (figure 5B). 
Thus in conclusion, recombinant MIP-2 was more effective on CD14-deficient than on 
wt PMNs. However the stronger effect of CSF was not mediated by MIP-2, but rather by 
cell wall products. These results indicate, that in CD14-/- mice not only increased 
chemokine levels in brain but also strongly migrating PMN contributed to the early CSF 
pleocytosis. 
 
2.6 CD14-/- mice show a stronger meningeal inflammation in CSF  
Intrathecal leukocytes are beneficial for bacterial killing and unfavourable 
mediators of inflammation. Since we found that early excess infiltration of leukocytes in 
CSF did not contribute to accelerated bacterial killing in CD14-/- mice, but on the 
contrary, allowed bacteria to accumulate in brain, we investigated the consequence of 
leukocyte infiltration on meningeal inflammation. 
TNF activity in CSF was higher in CD14-/- than wt mice 24 h after S. pneumoniae 
infection (figure 6A). Early after infection, at 6 and 12 h, TNF levels were below 10 
pg/mL, they peaked at 24 h and decreased after this time point. To investigate the cellular 
source of TNF in vivo, immunohistochemical stainings were performed in CSF cells 24 h  
after infection. Infiltrating cells were mainly PMN (80-90%), as identified by cytospin or 
flow cytometry using the granulocyte specific marker anti-Gr1 (data not shown). Nearly 
all PMN from both mouse strains contained intracellular TNF. Staining intensity was 
similar in CD14-/- and wt mice, when it was determined by immunoperoxidase (wt mice, 
a, and CD14-/-, b; figure 6B) or flow cytometry (data not shown). These results indicate 
that the high TNF levels in the absence of CD14 were not due to enrichment in TNF 
producing cells or to an increased production of intracellular TNF per cell. Most likely 
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the early higher leukocyte numbers was sufficient to explain the increased TNF 
concentration after 24 h. 
 
2.7 Infiltrating leukocytes are the major cellular source of TNF and TNF 
contributes to outcome 
To confirm that the excess number of infiltrating leukocytes were the cellular 
source of increased TNF in CD14-/- mice, we analyzed TNF mRNA expression in brains 
of infected mice which were depleted in leukocytes by cyclophosphamide pretreatment.  
Leukocytes from both mouse strains could be depleted in blood (mean ± SD, 87.7 ± 5.0% 
vs 76.7 ± 10.3% of depletion in CD14-/- and wt mice, respectively; P < .01, figure 7A), 
but infiltration into the CSF was not reduced by cyclophosphamide pretreatment in 
CD14-/- mice (mean ± SD, 0.2 ± 0.3% in CD14-/- vs 89.1 ± 15.9% of depletion in wt mice; 
figure 7B). Analysis of TNF mRNA expression by in situ hybridization in non-treated 
brains 24 h after infection, revealed a higher signal intensity in CD14-/- (figure 8A, b) than 
in wt mice (figure 8A, a). In leukocyte-depleted animals, the TNF mRNA signal was 
clearly reduced in CD14-/- (figure 8A, d) and completely abolished in wt mice (figure 8A, 
c). Moreover, combined in situ hybridization and immunohistochemistry of brain sections 
of mice showed a localization of TNF mRNA in CD45-positive leukocytes (mean ± SD, 
91.5 ± 7.0%, and figure 8B, a). Among these TNF-positive infiltrating cells, F4/80-
positive macrophages represented 86.4 ± 14.4% (figure 8B, b) and Gr1-positive 
granulocytes only 17.0 ± 8.1% (figure 8B, c). These results suggested that TNF was 
mainly derived from infiltrating cells. The distribution of TNF mRNA in brain cell 
subpopulations was similar in CD14-/- and wt mice. 
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Less than 10% of TNF-positive cells expressed the microglia marker Iba1 (figure 8B, e). 
In fact TNF-/Iba1-double positive cells were small and weakly Iba1-stained, thus 
probably representing Iba1-positive macrophages [27], while strongly Iba1-positive 
ramified cells resembled morphologically microglia and were never TNF-positive. 
Besides, the expression of CD45 by the large majority of TNF-positive cells, about 10% 
of the TNF-positive cells also stained for GFAP (figure 8B, d). Accordingly, CD45 and 
GFAP markers overlapped in a small fraction of cells; either anti-CD45 Ab stained 
astrocytes or some GFAP-positive cells expressed CD45.  
The TNF level in CSF was significantly correlated to the severity of disease 24 h 
after S. pneumoniae infection (r = 0.402; P < .01; figure 9). This suggested that the 
excess leukocytes in CD14-/- mice led to enhanced TNF and this most likely accelerated 
the course of the disease. 
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3. Discussion 
  In the present study, we investigated the in vivo function of CD14 in murine 
pneumococcal meningitis. We found that CD14-/- mice or wt animals pretreated with 
neutralizing anti-CD14 mAb were more susceptible to S. pneumoniae meningitis and died 
earlier. Our observations are in contrast to a previous study of Staphylococcus aureus 
sepsis [20]. In that mouse model, mortality was not significantly different in CD14-/- and 
wt mice. Possible explanations to these contradictory results might be that the authors 
used mice with an incomplete deletion of the CD14 gene, a different Gram-positive 
bacterial strain and a systemic infection model, while we investigated the role of CD14 in 
a local infection model with late sepsis. In agreement with the present study, others have 
shown a deleterious effect of CD14 blockade in mice after infection with Klebsiella 
pneumoniae [17] and rabbits infected with Escherichia coli K-1 [18] or Shigella flexneri 
[19]. 
The lack of CD14 did not impair systemic host defense, since similar bacterial counts 
were observed in blood and CSF of CD14-/- and wt mice. Moreover, brain bacterial load 
was not significantly different in CD14-/- and wt mice early in infection; This suggests 
that CD14 did not directly affect clearance of S. pneumoniae by host cells. Similar 
observations were made after in vitro infection of peritoneal macrophages [28], where E. 
coli binding and uptake did not differ in CD14-/- and wt cells. Our data in CD14-/- mice 
are in sharp contrast to those observed in TLR2-/- mice, which showed a slower bacterial 
clearing than wt mice during meningitis [29] and implies that CD14 is not involved in the 
TLR2-modulated bacterial phagocytosis [30] and killing. 
 76
In meningitis death occurs as a consequence of sepsis or of brain inflammation with 
edema. If CD14-/- mice did not die earlier from sepsis, death was most likely due to 
inflammation conferred by the early excess leukocyte infiltration. 
A strong influx of PMN into CSF is required for elimination of bacteria in meningitis, 
but an excessive number also contributes to brain inflammation and injury [31] [14] [32]. 
In an earlier study we found CD14 induced in PMN and in soluble form in CSF of 
pneumococcus-infected wt mice [33]. We did not know its function, now we showed that 
CD14 deficiency was associated with excess infiltrating PMN early in infection. Our 
findings are in agreement with a previous study, which described more infiltrating PMN 
in peritoneum of CD14-/- than of wt mice after i.p injection of E. coli [34]. This process 
of transmigration requires molecular interactions between receptors expressed on 
neutrophils and their endothelial counter-ligands.  The adhesion molecules, L-selectin, 
the three ß2-integrins (LFA-1, Mac-1 and gp 150) and ICAM-1 play a major role in PMN 
rolling, adherence and transmigration, respectively [35]. CD11/CD18 was shown to be 
particularly important in migration of PMNs into CSF during bacterial meningitis, since 
inflammation was markedly attenuated by anti CD11/CD18 treatment. [36] [37]. Since 
CD14 can associate with CD11b/CD18, the lack of CD14 may lead to a modulated 
CD11b/CD18 expression. [38]. We therefore investigated PMN adhesion molecules in 
blood and CSF. Our data demonstrated no differences in integrin or selectin cell surface 
expression in wt and CD14-/- mice. Further analysis of their counter-ligands in brain 
endothelia, including CD62-E (E-selectin), CD54 and vascular cell adhesion molecule-1 
(VCAM-1; CD106) revealed similar increased expression in brains of wt and CD14-/- 
mice after S. pneumoniae infection. In a recent in vitro study, PMN migration induced by 
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S. pneumoniae was not found dependent of ICAM-1, VCAM-1 or E-selectin expression 
in endothelial cells, since none of these adhesion molecules was upregulated in response 
to S. pneumoniae. Moreover, neutralizing Ab to CD54 did not prevent PMN migration 
[39]. This in vitro result contrasted with those results obtained in vivo in rat and rabbit 
bacterial meningitis, where intravenous treatment with anti-ICAM-1and anti CD18 mAb 
respectively reduced the influx of leukocytes into CSF [40] [36] [41] [37]. In agreement 
with these findings, our in vivo data revealed an up-regulation of integrins in PMN and 
ICAM-1, VCAM-1 in brain endothelial cells in pneumococcal meningitis. However, the 
stronger neutrophil migration observed in CD14-/- mice, following S. pneumoniae 
infection, did not correlate with up-regulation of any of these adhesion molecules. 
In addition to adhesion molecules, PMN require chemoattractants to direct their 
migration into the subarachnoid space. Chemokines and bacterial components are the best 
know candidates for leukocyte recruitment to inflammatory sites [42]. The CXC 
chemokine growth-related oncogene-α (GRO-α) was found in CSF of patients with 
bacterial meningitis and was shown to mediate chemotaxis in vitro [26]. In mice, MIP-2 - 
the murine homolog of GRO-α - was found released in CSF of mice infected with 
Listeria monocytogenes and similarly induced chemotactic activity in vitro [43]. The 
blockade of the keratinocyte-derived chemokine (KC; murine homolog of GRO-α) as 
well as MIP-2 or its receptor CXCR2 [44], has been demonstrated to reduced neutrophil 
migration in several mouse infection models [45] [46] [47] [48].  On the other hand, 
intracerebral injection of KC and MIP-2 resulted in neutrophil recruitment into the CSF 
[49]. In the present study, MIP-2 and KC concentrations in CSF, were similar in wt and 
CD14-/- mice, which is consistent with a previous observation excluding any correlation 
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between neutrophil counts and chemokine concentrations in CSF during bacterial 
meningitis [50]. Moreover, soluble ICAM-1 (sICAM-1), which has been previously 
found in high concentrations in CSF of patients with bacterial meningitis [21] did not 
differ in the two mouse strains. However, MIP-2 concentration in brain homogenates, 
which is derived from PMN-bound MIP-2 [22] and from resident cells, was 10-fold 
higher in CD14-/- than in wt mice. Thus, the absence of CD14 leads to an upregulation of 
chemokine release, which was not detectable in CSF. Besides the increased chemotactic 
ligand concentrations, we assessed the chemotaxis of mouse blood PMN towards the CSF 
of infected mice. In agreement with earlier studies, which demonstrate a chemotactic 
activity in CSF from mice [43] and patients [26] with bacterial meningitis, CSF from S. 
pneumoniae infected mice showed a chemotactic activity in vitro. However, the fact that 
neutralizing anti-MIP-2 and anti-KC mAbs failed to inhibit, even partially, CSF mediated 
chemotaxis, suggested the presence of additional, bacterial chemotactic factors or of very 
low chemokine concentrations in vivo. Some authors, using a rabbit model of 
pneumococcal meningitis, suggested that bacterial cell wall components contribute to the 
chemotaxis of CSF [51]. Indeed, peptidoglycan, lipoteichoic acid (LTA) and teichoic acid 
(TA), which are the most active components of pneumococcal cell wall (PCW), induced 
leukocyte pleocytosis in vivo after intracisternal injection into rabbits [52]. In our model, 
subarachnoidal injection of PCW induced a stronger neutrophil migration in CSF of 
CD14-/- than wt mice in vivo. Moreover, PMN from CD14-/- mice migrated more than wt 
PMN cells upon PCW in vitro. The fact that CSF from wt and CD14-/- mice showed 
similar chemotactic activity despite a stronger migration capacity of CD14-/- PMN, 
supports the conclusion that the chemotaxin was similar in both strains, but that CD14–
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deficient PMN had altered chemokine receptor expression chemotactic receptors or a 
stronger signalling. MIP-2 and KC are known to bind the same CXCR2 receptor on 
PMN, even if KC was 10-fold less potent than MIP-2 [53]. In addition, mice which lack 
CXCR2 receptor showed a severe impairment of neutrophil recruitment [44]. Recently, it 
has been shown that LPS, acts through Toll-like receptor 4 (TLR4) to downregulate 
expression of two specific kinases (GRK2 and GRK5) interacting with G-protein coupled 
receptor in response to MIP-2. This downregulation of GRK2 and GRK5 resulted in 
decreased CXCR2 receptor internalization and increased PMN migration [54]. Thus, it is 
tempting to hypothesize that a similar mechanism could be involved in our model of 
Gram-positive meningitis. i.e. CXCR2 might be upregulated in the absence of CD14 and 
TLR2 [55] [56] [57] [10].  
Our analysis of CD14/TLR2 in wt CSF cells showed that about 50% of the cells carry 
both TLR2 and CD14 and 35% have only TLR2, few have only CD14. We found earlier 
that TLR2-/- mice had a delay in leukocyte infiltration [29]. It is postulated that in these 
mice the presence of CD14 alone is insufficient to get the appropriate migration and 
chemokine release. On the other hand the presence of TLR2 alone in CD14 -/- mice, 
signals faster upon chemotaxins and induces more chemokines. This points to a newly 
recognized mutual role of CD14 and TLR2 in leukocyte migration.   
The stronger recruitment of PMN in CSF of CD14-/- mice was most likely associated 
with increased TNF release in CSF. Two observations supported this hypothesis. First, 
we found that TNF increased after neutrophil pleocytosis had started. Second, depletion 
of leukocytes by cyclophosphamide before infection showed downregulated TNF mRNA 
transcripts. Moreover, we could show by combined in situ hybridization and 
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immunohistochemistry that the TNF mRNA signal mainly colocalized with CD45+ 
infiltrating leukocytes. These data indicated that TNF was mainly derived from 
infiltrating cells. As reported previously, the consequence of meningeal inflammation is a 
disruption of the blood-brain barrier and therefore aggravation of the disease [29].  
 In conclusion, the present study clearly demonstrated that the lack or blockade of 
CD14 was associated with a stronger neutrophil recruitment into CSF, leading to 
excessive meningeal inflammation and aggravated disease after S. pneumoniae infection. 
This stronger neutrophil migration correlated with chemokine concentrations in brain and 
with an enhanced migratory capacity of CD14-deficient PMN. Our results show for the 
first time a direct implication of CD14 in regulation of neutrophil migration in mouse 
pneumococcal meningitis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 81
4. Materials and Methods 
4.1 Bacteria 
Streptococcus pneumoniae (clinical isolate of serotype 3) was grown for 7 h in 
double Mueller Hinton broth (MHB) (DIFCO Laboratories Detroit, USA), then 
subcultured overnight in new MHB, and washed in 0.9% sterile saline (12,000 x g for 6 
min) immediately before use. The inoculum size was calculated from optical density 
(OD) determinations at 620 nm (OD 0.4 = 1 x 108 CFU/mL) and was retrospectively 
assessed by CFU counting on blood agar plates. 
The unencapsulated Streptococcus pneumoniae derivative R6 strain (a kind gift from Dr. 
S. Leib, University of Bern, Switzerland) was grown in Brain-heart infusion (BHI) 
medium for 6 to 8 h at 35.2°C in 5.5% CO2, followed by subculture in fresh BHI medium 
to mid-logarithmic phase (optical density at 620 nm of 0.5). After washing, bacteria were 
killed by heating for 20 min at 80°C. Serial dilution were plated on blood agar plate and 
incubated at 37°C for 24 h to confirm the absence of growth. 
Pneumococcal cell wall (PCW) was prepared as described earlier with minor 
modification [52] [58] [59]. Streptococcus pneumoniae (clinical isolate of serotype 3) 
was grown to an OD of 0.5 at 620 nm (1.5 × 108 cfu/mL), chilled on ice, to prevent 
autolysis and centrifuged at 4°C at 4000 x g. After washing the pellet was resuspended in 
cold 50 mM Tris-HCl (pH 7.5) and placed in boiling 5% SDS solution for 15 min. After 
centrifugation at 10000 x g for 10 min, pellet was washed twice in 1 M NaCl and three 
times in distilled water to remove remaining SDS. The pellet was resuspended in water, 
added to an equal volume of sterile glass beads, and vortexed strongly for 5 min. After 
centrifugation at 700 x g for 10 min, the supernatant containing cell walls was 
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centrifuged again at 38000 x g for 15 min. The pellet was resuspended in 100 mM Tris-
HCl (pH 8.0) containing 20 mM MgSO4. DNase (10 µg/mL) and RNase (50 µg/mL) were 
added and incubated at 37°C for 2 h. Proteins were degraded overnight at 37°C in 100 
µg/mL trypsin containing 10 mM CaCl2. SDS was added to a final concentration of 1% 
and incubated at 60°C for 15 min. The solution containing cell walls was centrifuged at 
38000 x g for 15 min and washed three times in distilled water to remove remaining SDS. 
The pellet was centrifuged again at 38000 x g for 15 min and resuspended to a final 
concentration of 1 mg/ml in saline solution. 
 
4.2 Mouse meningitis models 
Six to eight week old C57BL/6 wt (RCC, Ittingen, Switzerland) and CD14-/- mice 
(kindly provided by MW. Freeman; Lipid Metabolism Unit, Massachusetts General 
Hospital, Harvard Medical School, Boston, Massachusetts, USA), which had been 
backcrossed for 6 generations on a C57BL/6 background) were kept under specific 
pathogen free conditions in the Animal House of the Department of Research, University 
Hospitals Basel according to the regulations of the Swiss veterinary law. Mice were 
anesthetized via intraperitoneal (i.p.) injection of 100 mg/kg Ketamine (Ketalar©; 
Warner-Lambert AG, Baar, Switzerland) and 20 mg/kg Xylazinum (Xylapan©; Graeub 
AG, Bern, Switzerland), and subsequently subarachnoidally inoculated into the left 
forebrain with either 0.9% NaCl, live Streptococcus pneumoniae (3 x 103 CFU), PCW 
(300 µg/kg) or heat-killed R6 strain (3 x 106 CFU). 
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In vivo CD14 blockade experiments were performed by pretreatment with i.v. injection of 
4C1 or isotype-matched control rat IgG2b mAbs 5 min prior to i.c. injection of 3 x 103 
CFU of live S. pneumoniae. The health status of the mice was assessed by the following 
scores as described previously [60] (1) normal motor activity and turned upright in < 5s 
when put on their back; (2) decreased spontaneous activity, but still turned up in < 5s; (3) 
turned up in > 5s; (4) did not turn up; (5) did not move. After 6, 12, 24, 48 and 72 h or if 
they presented score 5, mice were sacrificed by i.p. injection of 100 mg/kg pentobarbital 
(Abbott Laboratories, North Chicago, IL). Blood was obtained by intracardiac puncture 
and collected in EDTA. Animals were perfused with Ringer’s solution (Braun Medical 
AG, Emmenbrücke, Switzerland) into the left cardiac ventricle until the effluent became 
clear. Cerebrospinal fluid (CSF) was obtained by puncture of the cisterna magna as 
described previously [61]. Due to the small volumes (3-6 µL) obtained from each animal; 
CSF from 2 to 3 mice was pooled in some experiments. 
For the leukocyte depletion treatment, cyclophosphamide (Sigma) was reconstituted with 
sterile PBS and injected i.p. (300 mg/kg in 0.2 mL) 48 h before S. pneumoniae 
inoculation. 
 
4.3 Real-time in vivo imaging study of meningitis using bioluminescent S. 
pneumoniae transformed with Gram-positive lux transposon 
Mice were subarachnoidally injected with 3 x 103 CFU luciferase-tagged S. 
pneumoniae serotype 3 (Xen10) and subsequently shaved for better imaging. This 
bacterial strain, kindly provided by L. Chen (Xenogen Corporation, Alameda, CA) was 
constructed as described previously [62]. 
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After infection, analysis of photons was performed repeatedly in mice under isoflurane 
inhalation anesthesia in an IVIS CCD (charge-coupled device) camera  (Xenogen 
Corporation, Alameda, CA) coupled to the LivingImage software package (Xenogen 
Corporation, Alameda, CA). 
 
4.4 Determination of bacterial counts and inflammatory parameters 
 Blood samples collected in EDTA and pooled CSF samples were serially diluted 
in 0.9% saline to assess the bacterial load after plating and incubation at 37°C for 24 h. 
CSF samples were centrifuged at 800 x g for 7 min (room temperature) to obtain cell free 
CSF. Thereafter, they were stored at -20°C until cytokine and chemokine determinations. 
The pelleted CSF cells were counted and identified via cytospin or phenotypically 
analyzed. Brains were removed and homogenized with a Polytron homogenizer in 1 mL 
of 0.1 mol/L PBS. Bacterial titers were determined by plating serial 10-fold dilutions in 
0.9% saline on blood agar plates. For in situ hybridization, brains were fixed in 4% 
paraformaldehyde (Aldrich) and embedded in paraffin blocks. 
The concentration of the pro-inflammatory cytokine TNF in CSF was determined with a 
bioassay, measuring the degree of cytotoxicity on WEHI cells in the presence of 1 µg/mL 
actinomycin D, using mouse rTNF as a standard. Soluble ICAM-1 and the chemokine 
MIP-2 and KC levels in CSF were measured by ELISA Kits (R&D Systems Europe, 
Abingdon, UK) according to the instructions of the manufacturers. 
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 4.5 Preparation of peripheral blood-derived polymorphonuclear (PMN) cells for 
chemotaxis 
Mouse blood was harvested by intracardiac puncture and collected in EDTA and 
PMN were isolated by density gradient centrifugation on a discontinuous Percoll gradient 
with 59 and 67% Percoll (Percoll, Pharmacia Biotech AB, Uppsala, Sweden) in PBS as 
previously described [63]. The interface of the 59 and 67% Percoll layers, which contains 
the PMN, was collected and contaminating erythrocytes were removed by hypotonic lysis 
in water. By morphologic criteria, the final cell preparation contained > 97% PMN and 
was used at a concentration of 6.9 x 105 cells/mL in chemotaxis assays. The viability of 
the cells, as assessed by trypan blue exclusion, was >95%.    
 
4.6 Chemotaxis assay 
Migration of mouse PMN was assessed in vitro using 48-well microchemotaxis 
chambers as previously described [43]. Dilutions of samples or CSF diluted ½ (v/v) in 28 
µL Hanks Hepes buffer were added to the lower wells in triplicates. A 
polyvinylpyrrolidone-free polycarbonate filter membrane (3 µm pore size; Nuclepore, 
Sterico AG, Dietikon, Switzerland) was placed between the lower wells and the upper 
wells containing 45 µL of cell suspensions (6.9 x 105 cells/mL in Hanks Hepes buffer). 
The chemotaxis chambers were incubated for 60 min at 37°C in 5% CO2 in humidified 
air. After incubation, the filters were removed, fixed and stained with Wright-Giemsa. 
The number of cells that migrated through the pores of the filter was counted in 6 high-
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powered fields (x 63). Cell migration was expressed as the mean percentage of PMN that 
migrated per well. Hanks Hepes buffer alone was used as a control for random migration, 
and N-formylmethionyl-leucyl-phenylalanine (fMLP, Sigma Chemical Co.) as a positive 
control at concentration 10-6 M. 
For neutralization experiments, CSF samples were preincubated with anti-MIP-2 (30 
µg/mL) or control rat IgG2b (30 µg/mL) mAbs for 120 min at 37°C. 
 
4.7 Microvascular endothelial cell cultures 
Brain-derived microvascular endothelial cells (MVEC) were isolated from 6-12 
week old C57BL/6 or CD14-deficient mice of either sex according to published methods 
[64] [65] [66] with slight modifications. Briefly, the brain was aseptically removed and 
cortical tissue was cleaned of meninges and superficial vessels using fine foreceps under 
a binocular microscope. The cortices were transferred into cold DMEM (Gibco, 
Invitrogen AG, Basel Switzerland) supplemented with 5% FCS (PAA Laboratories, Linz, 
Austria), 0.4 mM N-acetyl-L-alanyl-L-glutamine (Biochrom, Berlin, Germany) and 20 
µg/mL gentamycin (Sigma, Fluka AG, Buchs, Switzerland) (DMEM/5%), cut into small 
pieces and homogenized with a 10 mL-syringe. Dispase II solution (Roche, Rotkreuz, 
Switzerland) was added to a final concentration of 0.2% (0.096 U/mL) and preparation 
was allowed to digest for 1 h at 37°C under stirring in a water bath. The homogenate was 
centrifuged (1000 x g, 10 min, 4°C) and the supernatant removed. The pellet was 
resuspended in 2 mL DMEM containing 20% dextran (MW = 71327, Sigma), 
homogenized with a fire-polished pipette and centrifuged (1700 x g, 10 min, 4°C). The 
top layer containing most of the myelin was discarded and the pellet resuspended in 
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DMEM/5%, layered onto 13% dextran solution in DMEM and centrifuged (1700 x g, 10 
min, 4°C) to remove remaining myelin. Thereafter, the pellet was suspended in 
DMEM/5% and digested for 30 min at 37°C with collagenase/dispase (Roche) and 
DNase I (Sigma) at a final concentration of 1 mg/mL and 0.05 mg/mL, respectively. The 
cells were centrifuged (380 x g, 10 min, 4°C), washed twice with DMEM/5% and plated 
on collagen I-coated culture dishes (60 mm diameter, BioCoat, Becton Dickinson, Basel, 
Switzerland). The culture medium was composed of DMEM containing 20% FCS, 20 
µg/mL endothelial cell growth supplement (ECGS, Serva, Heidelberg, Germany), 2 mM 
N-acetyl-L-alanyl-L-glutamine, 20 µg/mL gentamycin and 16 U/mL heparin (Sigma). 
Cells were grown at 37°C in a humidified 8% CO2 atmosphere. Two days after seeding, 
cells were washed with HBSS and fresh medium was added. Thereafter, the medium was 
replaced every 2 days. MVEC were grown to confluence and passaged between day 6 
and 9. Based on their expression of von Willebrand Factor (Dako, Glostrop, Denmark) 
and uptake of Dil AcLDL (Molecular Probes, Yuro Supply, Lucerne, Switzerland) the 
MVEC cultures were found to have a purity of at least 90%. Cells were trypsinized 
(0.25% Trypsin/EDTA, Biological Industries, Kibbutz Beit Haemek, Israel) and seeded 
either in collagen I-coated culture dishes (0.2 Mio. cells/dish, 35 mm diameter, BioCoat) 
or 96-well F-plates (2 x 104 cells/well, BioCoat). After overnight culture, the medium was 
replaced with fresh culture medium without gentamycin and infected with viable S. 
pneumoniae at a multiplicity of infection (MOI) of 2, 10 and 20. In some experiments, 
the bacteria-containing medium was removed 2 h later, the cells were washed twice with 
PBS and replaced with fresh DMEM culture medium supplemented with 100 µg/mL 
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gentamycin to prevent extracellular bacterial growth. Supernatants were harvested 8 and 
24 h later, centrifuged (2000 x g, 15 min, 4°C) and stored at -20°C until ELISA analysis. 
 
4.8 Immunocytochemistry for TNF 
 Conventional avidin-biotin system immunocytochemistry was carried out with 
some modifications as previously described [67]. CSF cells from S. pneumoniae infected 
mice were harvested and collected directly in RPMI 5% FCS containing Brefeldin A 
(Sigma) at 10 µg/mL and plated in 16-well glass LabTekTM chamber slides (Nalge Nunc, 
Naperville, IL) for 2 h at 37°C. Cells were washed and fixed with ice cold 4% 
paraformaldehyde for 5 min. The fixative was removed and cells were washed in wash 
solution composed by Hanks’ balanced salt solution (HBSS, Life Technologies GIBCO), 
10 mM Hepes (Calbiochem) and 0.1% Saponin (Sigma). Endogenous peroxidase activity 
was blocked by incubating cells with 0.3% H2O2 in wash solution for 20 min at RT. After 
washing, cells were incubated overnight at 4°C with rat anti-mouse TNF (BD 
Pharmingen 554641) or rat IgG1 mAbs at 40 µg/mL in wash solution containing 2% 
normal rabbit serum. After washing, cells were incubated 1 h at RT with a secondary 
biotinylated rabbit anti-rat Ab (Vector Laboratories, Burlingame, CA) at a dilution of 
1/200, followed by incubation with avidin/biotinylated-peroxidase complexes (Vectastain 
Elite ABC, Vector Laboratories) for 30 min. Cells were then rinsed with 0.05 M Tris-HCl 
pH 7.6 and incubated with peroxidase substrate 3-amino-9-ethyl carbazole (DAKO 
Corporation, Carpinteria, CA) for 5 min. After rinsing in distilled water, cells were 
counterstained with hematoxylin (Medite, Nunningen, Switzerland) for 40 s and 
mounted.  
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4.9 cRNA probes and in situ hybridization 
 Plasmids were linearized and the sense and antisense riboprobes synthesized as 
described [68]. Radioactive cRNA copies were synthesized by incubation of 250 ng 
linearized plasmid in MgCl2 6 mM, Tris (pH 7.9) 40 mM, spermidine 2 mM, NaCl 10 
mM, dithiothreitol 10 mM, ATP/GTP/CTP 0.2 mM, 100 µCi of α-35S-UTP (Dupont 
NEN, #NEG 039H), 20 U RNAsin (Promega, Catalys, San Luis Obispo, USA) and 10 U 
of either T7, SP6 or T3 RNA polymerase for 60 min at 37 °C. Unincorporated 
nucleotides were removed using ammonium-acetate precipitation method; 100 µL of 
DNAse solution (1 µL DNAse, 5 µL of 5 mg/mL tRNA, 94 µL of 10 mM Tris / 10 mM 
MgCl2) was added, and 10 min later, a phenol-chloroform extraction was performed. The 
cRNA was precipitated with 80 µL of 5 M ammonium acetate and 500 µL of 100% 
ethanol for 20 min on dry ice. The pellet was dried and resuspended in 50 µL of 10 mM 
Tris/1 mM EDTA. A concentration of 107 cpm/probe was mixed into 1 mL of 
hybridization solution (500 µL formamide, 60 µL 5 M NaCl, 10 µL 1 M Tris [pH 8.0], 2 
µL 0.5 M EDTA [pH 8.0], 50 µL 20x Denhart's solution, 200 µL 50% dextran sulfate, 50 
µL 10 mg/mL tRNA, 10 µL 1 M DTT, [118 µL DEPC water - volume of probe used]). 
This solution was mixed and heated for 10 min at 65 °C before being spotted on slides. 
Hybridization histochemical localization of TNF mRNA was carried out on every twelfth 
sections of the whole rostro-caudal extent of each brain using 35S-labeled cRNA probes 
as described previously [68].  The sections were exposed at 4 °C to X-ray films (Biomax, 
Kodak, Rochester, NY) for 1-3 days.  The slides were thereafter defatted in xylene, 
dipped in NTB-2 nuclear emulsion (Kodak; diluted 1:1 with distilled water), exposed for 
10 days. The slides were then developed in D19 developer (Kodak) for 3.5 min at 14-
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15°C, washed 15 s in water, and fixed in rapid fixer (Kodak) for 5 min.  Tissues were 
thereafter rinsed in running distilled water for 1 h, counterstained with thionin (0.25 %), 
dehydrated through graded concentrations of alcohol, cleared in xylene, and coverslipped 
with distrene plasticizer xylene (DPX) mounting medium (Electron Microscopy Science, 
Washington, PA). Signal intensity was quantified with the NIH Image software. 
 
4.10 Statistical analysis 
 Differences in survival between wt and CD14-/- mice were tested using the log 
rank test and Kaplan-Meier analysis. Results of the CFU in brain homogenates, leukocyte 
numbers in blood and CSF and the chemotactic activity of CSF samples were compared 
using the Mann-Whitney U test. Differences in chemokine and sICAM-1 levels in CSF 
between wt and CD14-/- mice were analyzed with the non-parametric Wilcoxon Signed 
rank test.  
The relationship between two parameters (parametric variables) was assessed in a linear 
regression model using Spearman rank correlation test. In all statistical tests, a P < .05 
was considered statistically significant. 
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Figure 1. A, Survival of CD14-/- and wt mice after infection with 3 x 103 CFU of S. 
pneumoniae. CD14-/- mice (dashed line; n = 22) showed earlier death as compared to wt mice 
(solid line; n = 21) (P < .02). 
 B, Effect of CD14 blockade on survival of wt mice after infection with S. pneumoniae. Mice 
were treated i.v. with 5 mg/kg of either rat anti-CD14 (4C1) (dashed line; n = 11) or isotype- 
matched control rat IgG2b (solid line; n = 12) mAbs 5 min prior infection. Anti-CD14 treated 
mice died earlier than animals receiving isotype-matched control mAb (P < .02). 
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Figure 2. Time course of infection in CD14-/- and wt mice after infection with 3 x 103 CFU 
of luciferase-tagged S. pneumoniae. A, Emitted photons in live animals were detected by a highly 
sensitive CCD camera (IVIS imaging system; Xenogen), and images from one animal out of 9 at 
0.5, 2, 6, 12 and 24 h after infection are shown. 
B, Emitted light was also quantified by LivingImage software and expressed as Photons/s/cm2. 
CD14-/- brains showed more emitted photons [left] and more CFU [right] than wt brains 24 h after 
infection (P < .01).  
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Figure 3. Time course of CSF pleocytosis in CD14-/- and wt mice after injection with either 
(A) live S. pneumoniae (3 x 103 CFU) or (B) PCW (300 µg/kg). CSF was collected at indicated 
times and infiltrating leukocytes were counted at 6 h (n = 15), 12 h (n = 11) and 24 h (n = 11). 
Results are represented as mean ± SD. *P < .05. 
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Figure 4. A, Time course of MIP-2 levels in brain homogenates after infection with 3 x 103 
CFU of S. pneumoniae. Mean + SD of 3 experiments are shown. * P < .05. 
B, Time- and MOI-dependent MIP-2 production by CD14-deficient and wt brain-derived 
microvascular endothelial cells. Mean of triplicate cultures are shown. 
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Figure 5. Chemotactic activity mediated by either CSF from CD14-/- and wt mice 
(subarachnoidally injected with 3 x 106 CFU of heat killed R6 S. pneumoniae) or by PCW. A) 
CSF (final concentration of 50%), treated or not with neutralizing anti-MIP-2 (30 µg/mL) or 
PCW (3 µg or 0.03 µg), (B) rmMIP-2 (2 ng/mL) with or without neutralizing anti-MIP-2 (30 
µg/mL) was placed into the lower wells of a 48-well microchemotaxis chamber and the 
chemotactic activity upon blood PMN was measured. 
The percentage of migrated neutrophils was determined by counting 600 to 900 cells per well. 
Mean ± SD of three independent experiments. * P < .05; ** P < .01. 
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Figure 6. A, Time course of TNF release into the CSF of CD14-/- and wt mice after 
infection with 3 x 103 CFU of S. pneumoniae. 
CSF was collected at indicated times and TNF levels were determined by a TNF bioassay. Mean 
± SD of three independent experiments. * P < .05. 
B, Intracellular TNF staining of CSF infiltrating PMN harvested from CD14-/- and wt mice 24 h 
after infection. Cells from CD14-/- (b and d) and wt (a and c) mice were stained for intracellular 
with anti-TNF (40 µg/mL) (a and b) or control rat IgG1 (40 µg/mL) (c and d) mAbs by 
immunocytochemistry. Similar staining intensities were observed in CD14-/- and wt PMN. 
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Figure7. Leukocyte numbers in (A) blood (n = 15 or 17) and (B) CSF (n = 9 or 11) in non 
treated and leukocyte-depleted animals 24 h after infection with 3 x 103 CFU of S. pneumoniae. 
300 mg/kg of cyclophosphamide was injected i.p. 48 h before S. pneumoniae inoculation. 
Mean ± SD of three independent experiments. * P < .05. 
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Figure 8. In situ hybridization of TNF mRNA in brains from CD14-/- and wt mice 24 h 
after infection with 3 x 103 CFU of S. pneumoniae. A, Bright field photomicrographs of coronal 
brain cryosections (20 µm) hybridized as described in Materials and Methods. Expression of 
TNF mRNA transcripts in non treated (a and b) and leukocyte-depleted (c and d) infected 
animals. Results from one experiment representative of three independent experiments are shown 
(CD14-/-, b and d; wt, a and c). 
B, Colocalization of TNF mRNA in infiltrating and brain resident cells in mouse brains 24 h after 
infection with 3 x 103 CFU of S. pneumoniae. (a) CD45, (b) F4/80, (c) Gr1, (d) GFAP and (e) 
Iba1 immunostainings were performed on brain sections. Large arrows, TNF mRNA-positive 
cells; small arrows, double-labelled cells. 
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Figure 9. Association between disease severity and TNF release in CSF of mice after 
infection with 3 x 103 CFU of S. pneumoniae. The disease severity was assessed as described in 
Materials and Methods.  
The correlation between TNF activity and severity of the disease was assessed in a linear 
regression model using a Spearman rank correlation test. ** P < .01. Filled circles = wt mice (n = 
7), open circles = CD14-/- mice (n = 9). 
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Table I. Bacterial load in blood and CSF of CD14-/- and wt mice after infection 
with 3 x 103 CFU of S. pneumoniae. 
 CFU/mL of 
blood 
 CFU/µL of 
CSF 
 
Hours after infection 24 h 6 h 12 h 24 h 
wt 
CD14-/-
    50 ± 300 
    40 ± 300 
89 ± 87 
52 ± 18 
5217 ± 6268 
10150 ± 6784 
31775 ± 37750 
28288 ± 20375 
NOTE. CFU were determined in blood and CSF as described in Materials and Methods. Data are 
presented as median ± SD. Similar CFU numbers in CD14-/- and wt mice (P > .05). 
 
 
 
 
 
 
Table II. MIP-2, KC and sICAM-1 levels in CSF of CD14-/- and wt mice 6 and12 h 
after i.c. infection with 3 x 103 CFU of S. pneumoniae. 
Mouse strain wt  CD14-/-  
Hours after 
infection 
6 h 12 h 6 h 12 h 
 
MIP-2 (pg/mL) 
KC (pg/mL) 
sICAM-1 (ng/mL) 
395 ± 341 
1820 ± 1640 
2435 ± 1667 
1747 ± 1708 
9830 ± 7262 
2389 ± 893 
623 ± 651 
4851 ± 4923 
2753 ± 1334 
2740 ± 2711 
11662 ± 9720 
2495 ± 464 
NOTE. MIP-2, KC and sICAM-1 measurements were determined in CSF from 5 to 6 mice using 
an ELISA kit. Data are presented as mean ± SD. Similar chemokines and sICAM-1 levels in 
CD14-/- and wt mice (P > .05). 
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Abstract  
 
Toll-like receptor (TLR)-2 and CD14 mediate host responses to Gram-positive bacterial 
wall components. TLR2-/-, CD14-/- and TLR2-/-/CD14-/- (double Knockout, KO) mice 
died earlier from murine Streptococcus pneumoniae meningitis than wt mice. Modulation 
of outcome by antibiotic and TNF-alpha converting enzyme (TACE) inhibitor treatment 
was evaluated in the four mouse strains. The three KO and the wt strain underwent 
ceftriaxone therapy. All wt, CD14-/- and TLR2-/-/CD14-/- mice were rescued, 27% of the 
TLR2-/- mice died (P < .04). Treatment failure in TLR2-/- mice was related to high 
bacterial load and cerebrospinal fluid TNF levels in this strain. TACE inhibitor treatment 
significantly reduced TNF in CSF in TLR2-/- mice. It did not rescue, but prolonged 
survival in TLR2-/- and CD14-/- mice to the values observed in untreated wt mice. 90% of 
TLR2-/- mice were rescued by combined antibiotic and TACE inhibitor treatment. TLR2-/-
/CD14-/- mice behaved during meningitis like single CD14-/- mice. This illustrates that the 
two pattern recognition receptors TLR2 and CD14 have differing functions in vivo.  
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Introduction 
  
 Streptococcus pneumoniae is the cause of the most severe and most frequent form 
of adult bacterial meningitis (1). The case fatality rate remained unchanged at 25% since 
20 years and intracranial complications with neurological sequelae are frequent (2). In 
view of increasing resistance of pneumococcus against beta-lactam antibiotics (3), new 
treatment strategies are required. Adjuvant therapy with dexamethasone is used in 
children and adults. Pathophysiological parameters and outcome have been found 
improved (4). Experimental studies have however shown a neurotoxic potential of 
steroids (5). Therefore other adjunctive therapies (6) have been evaluated which all aimed 
at reducing inflammatory components or toxic products released by inflammatory cells. 
TNF and matrix metalloproteases are major targets, both molecules are upregulated early 
during meningitis (7) and TNF contributes to brain injury in this disease (8, 9). TNF and 
its receptors are shed from the membrane by TNF alpha converting enzyme (10). A 
recently developped combined inhibitor of matrix metalloproteases and TNF alpha 
converting enzyme has proven non toxic and efficient in experimental meningitis and has 
initiated a new therapeutic area in bacterial meningitis (8).  
 TLR2 recognizes microbial components and mediates inflammatory responses to 
cell wall peptidoglycan, cell wall and teichoic acid, and membrane lipoproteins of Gram-
positive bacteria (11, 12). Direct TLR2 binding was shown only for peptidoglycan (13); 
binding sites for the other ligands have not been identified. Live Gram-positive bacteria, - 
although they express TLR2 ligands on their surface - do not depend on TLR2 for 
phagocytosis and killing, nor for induction of inflammation, but TLR2 modulates 
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phagocytosis and inflammation. The mechanism and direction of TLR2 action was found 
variable depending of the disease model. In pneumococcal meningitis and in Borrelia 
arthritis, bacterial clearance was accelerated by TLR2 (9, 14, 15). In contrast, in 
pneumococcal pneumoniae bacterial clearance was unaltered in TLR2-/- mice (16). 
Finally, modulation of inflammation by TLR2 was not restricted to Gram-positive 
infections. Indeed, a virulence factor released from Gram-negative Yersinia colitis 
induced IL-10 production and thereby immunosupression in a TLR2-dependent way, 
therefore in this model TLR2-deficient mice were less susceptible than wt mice (17).  
 The glycosylphosphatidylinositol-anchored CD14 binds lipopolysaccharide, 
peptidoglycan and lipoteichoic acids (18). It does not transmit a signal on its own, but 
most likely is the major ligand binding element and associates with TLR2 for signaling 
(11, 19). This conclusion comes from TLR2 and CD14-transfected cells, where CD14 
alone did not cause but enhanced TLR2-mediated NFkB activation (11). Furthermore, in 
human monocytes anti-CD14 antibodies were able to completely prevent cytokine release 
induced by Gram-positive components, indicating that in these cells which coexpress 
CD14, and TLR2, CD14 is upstream TLR2 (18). Anti-CD14 pre-treatment led to a late 
delay in bacterial clearance in a rabbit E. coli pneumonia model (20), and to a more 
severe bacterial invasion and tissue destruction in shigellosis in rabbits (21). Bactericidal 
activity upon E. coli but not upon Shigella was found altered by anti-CD14 (21, 22), thus 
other defense mechanism may also be affected by CD14 including PMN migration and 
inflammatory product release. In murine Gram-positive infection, CD14 deletion was not 
associated with an altered disease outcome but with increased TNF levels in serum (23). 
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The deleterious outcome of TLR2-/- mice in meningitis was published by our group (9), 
the outcome of CD14-/- mice with meningitis has also recently been described by us and 
has been found similarly unfavorable (24). However, we observed that the two receptors 
conferred protection by different mechanisms. While the lack of TLR2 delayed bacterial 
clearance, leukocyte infiltration and enhanced inflammation by an unresolved pathway 
(9), the lack of CD14 had no effect on bacterial clearance, but led to enhanced 
inflammation by accelerating leukocyte infiltration into the CSF (24). In view of our 
observations, that different host effector functions were modulated by TLR2 and CD14 
during meningitis, we asked the question whether response to therapy was also dependent 
on the presence of these two molecules. Therefore we compared the outcome in wt, 
TLR2-/- and CD14-/- mice with meningitis under antibiotic treatment and/or anti-
inflammatory treatment with TACE inhibitor TNF484. In addition we investigated the 
course of meningitis and the treatment response of TLR2-/-/CD14-/- mice.  
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Materials and Methods 
 
Preparation of bacterial inocula 
 Streptococcus pneumoniae (clinical isolate of serotype 3, H14) was grown for 7 h 
in double Mueller Hinton broth (MHB) (DIFCO Laboratories Detroit, USA), then 
subcultured overnight in new MHB, and washed in 0.9% sterile saline (12,000 x g for 6 
min) immediately before use. The inoculum size was calculated from optical density 
(OD) determinations (OD 0.4 = 1 x 108 cfu/mL) and was retrospectively assessed by 
CFU counting on blood agar plates.  
 
Mouse meningitis model 
 Six to eight week old C57BL/6 (wild-type, wt), TLR2-/- mice were kindly 
provided by William J. Rieflin from Tularik, South San Francisco, CA) and CD14-/- mice  
were kindly provided by Mason Freeman, Massachusetts General Hospital, Boston. The 
two strains with targeted gene deletions were crossed to obtain TLR2-/-/CD14-/- double 
knockout mice. All animals were kept under specific pathogen free conditions in the 
Animal House of the Department of Research, University Hospitals Basel according to 
the regulations of the Swiss veterinary law. Both transgene mouse strains had been 
backcrossed for 6 generations on a C57BL/6 background). Mice were anesthetized via 
intraperitoneal (i.p.) injection of 100 mg/kg Ketamine (Ketalar©; Warner-Lambert AG, 
Baar, Switzerland) and 20 mg/kg Xylazinum (Xylapan©; Graeub AG, Bern, Switzerland), 
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and subsequently subarachnoidally inoculated into the left forebrain with either 25 µL 
0.9% NaCl or live Streptococcus pneumoniae (2 x 102 or 3 x 103 cfu).  
The health status of the mice was assessed by the following scores as described 
previously (8) (1) normal motor activity and turned upright in < 5s when put on their 
back; (2) decreased spontaneous activity, but still turned up in < 5s; (3) turned up in > 5s; 
(4) did not turn up; (5) did not move. After 6, 12, 24, 48 and 72 h or if they presented 
score 5, mice were sacrificed by i.p. injection of 100 mg/kg pentobarbital (Abbott 
Laboratories, North Chicago, IL). Animals were perfused with Ringer’s solution (Braun 
Medical AG, Emmenbrücke, Switzerland) into the left cardiac ventricle until the effluent 
became clear. Cerebrospinal fluid (CSF) was obtained by puncture of the cisterna magna 
as described previously (25) Due to the small volumes (3-6 µL) obtained from each 
animal, CSF from 3 mice were pooled. 
 
Treatment  
 Mice were treated with either 80 mg/kg ceftriaxone (Rocephin, Hoffmann-La 
Roche, Switzerland, dissolved in 0.1 mL saline) via i.p. injection twice daily during 5 
days and/or with subcutaneous (s.c.) injection of 1 mg/kg water soluble inhibitor of 
matrix metalloproteases and TACE TNF484 twice daily during 4 days. Treatment with 
antibiotics was started 18 h and treatment with TACE inhibitor was started 12 h after 
infection.  
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Determination of bacterial counts and inflammatory parameters 
 Pooled CSF samples were serially diluted in 0.9% saline to assess the bacterial 
load after plating and incubation at 37°C for 24 h. Thereafter it was centrifuged at 800 x g 
for 7 min (room temperature) to obtain cell free CSF. Thereafter, samples were stored at -
20°C until cytokine determination. Brains were removed and homogenized with a 
Polytron homogenizer in 1 mL of 0.1 mol/L PBS. Bacterial titers were determined by 
plating serial 10-fold dilutions in 0.9% saline on blood agar plates. The concentration of 
the pro-inflammatory cytokine TNF in CSF was determined with a bioassay, measuring 
the degree of cytotoxicity on WEHI cells in the presence of 1 µg/mL actinomycin D, 
using mouse rTNF as a standard.  
 
Statistical analysis 
 Differences in survival between different mouse strains and treatments were 
analyzed using the log rank test and Kaplan-Meier analysis. Data of disease severity 
scores were assessed by ANOVA corrected for repeated measurements, followed by post 
hoc analysis (Fisher’s PLSD, Scheffe and Bonferroni/Dunn tests). Differences in CSF 
parameters between wt, TLR2-/- and CD14-/- mice were analyzed with the non-parametric 
Kruskall Wallis test. In all statistical tests, P < .05 was accepted statistically significant. 
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Results 
 
Effect of TLR2- and CD14-deficiency on survival in pneumococcal meningitis  
 We and others have previously shown that TLR2 is protective in pneumococcal 
meningitis, since TLR2-deficient mice presented a higher disease severity both in an 
intracisternal and a subarachnoidal meningitis model and died earlier than wt mice (9, 
14). Similarly, we could show, that CD14-/- mice died earlier during pneumococcal 
meningitis than wt mice (24). 
 
Antibiotic treatment of meningitis in TLR2-/-- and CD14-/- mice 
 Antibiotic treatment is efficient in mouse (26) and human meningitis (27), if 
treatment starts early. Accordingly, ceftriaxone was administered starting as early as 18 h 
after infection. All wt and CD14-/- mice were rescued (figure 1A and B), whereas 27% of 
TLR2-/- mice still died, which was significantly different from the outcome in wt mice (P 
<.05). The higher bacterial load in the former strain explained the difference between 
TLR2-/- and CD14-/- mice in response to antibiotics. Indeed, we previously showed that 
TLR2-/- mice had a significantly higher bacterial brain load than wt mice, starting two 
hours after infection (9). In contrast, CD14-/- mice had similar numbers of cfu as wt mice 
in brain up to 24 h after infection (3.2 ± 2.4 x 103 and 4.9 ± 3.8 x 103 CFU/brain, 
respectively 3 h after infection). Therefore it can be concluded that the high bacterial 
number in TLR2-/- mice rapidly precluded rescue by antibiotics alone but required anti-
inflammatory treatment. 
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Effect of TACE inhibitor on meningitis in TLR2-/-- and CD14-/- mice 
 Since TLR2-/- mice could not be rescued with antibiotics, it was likely that the 
higher bacterial load in this strain led to excess inflammation, which contributed to their 
bad prognosis. Indeed TLR2-/- mice presented higher TNF concentrations in CSF 24 h 
and 48 h after infection than wt mice (9). This TNF was significantly related to blood 
brain barrier disruption and to disease severity (9). In the present study we confirmed that 
TNF in CSF was higher in TLR2-/- than in CD14-/- or wt mice (figure 2). Therefore we 
aimed at a TNF-reducing therapy with the TACE inhibitor TNF484. To confirm, that this 
substance blocked TNF in our model, TNF was measured in CSF of mice, which had or 
had not received TNF484 treatment 12 h after infection with S. pneumoniae. TNF was 
reduced from 1424 ± 824 pg/mL in TLR2-/- and from 191 ± 271 pg/mL in wt CSF to non-
measurable values in both mouse strains during treatment with TACE inhibitor. Outcome 
was followed in infected TLR2-/-, CD14-/- and wt mice, which were treated for 5 days 
with TNF484 (figure 3). No mice were rescued to 100% survival, but mortality was 
significantly delayed by TNF484 treatment in the KO strains. In TLR2-/- and CD14-/- 
animals, this therapy significantly slowed death (P < .05) to the rate observed in untreated 
wt mice (figure 3A and 3B). Survival of wt mice was non-significantly prolonged by the 
TACE inhibitor treatment (figure 3A and 3B, P > .05). These results indicate that TLR2 
deficient mice with a high degree of inflammation profited best from TNF484.  
  
Effect of antibiotics and TACE inhibitor combined in TLR2 -/- mice 
 All wt and CD14-/- mice, but not TLR2-/- mice were rescued by antibiotics 
According to the individual effects of ceftriaxone and TNF484 in TLR2-/- mice, an 
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additive result was expected by combining both treatments. Therefore this combination 
therapy of TNF484 and antibiotics was started 12 and 18 h after infection respectively. 
Wild-type mice were rescued as expected and TLR2-/- mice were significantly improved 
(P <.01), they had 89% survival rate, which was not significantly different from wt mice.   
 
Survival and treatment effects in TLR2-/-/CD14-/- mice 
 According to in vitro cell activation studies, both CD14 and TLR2 have a receptor 
function for cell wall components of Gram-positive bacteria including peptidoglycan and 
lipoteichoic acid (11, 19, 28). During experimental meningitis, each molecule was found 
to have a protective effect on its own, which was exerted by different mechanisms. The 
lack of TLR2 delayed bacterial clearance. Table 1 illustrates these findings by 
comparison of the fold increase in brain bacterial numbers between 6 h and 12 h after 
infection. The increase was 220 and 134 fold in wt and CD14-/- mice respectively, but 
twice as high, namely 442 fold in TLR2-/- mice. In addition, the lack of TLR2 delayed 
leukocyte infiltration, while the lack of CD14 accelerated infiltration (9, 24). Table 1 
again demonstrates these findings; between 6 and 12 h after infection, leukocyte numbers 
increased 10 fold in wt, 2 fold in TLR2-/- and 22 fold in CD14-/- mice. Twenty four hours 
after infection TLR2-/- mice showed the strongest i.e. a 408 fold TNF increase in CSF, it 
was less in CD14 (333 fold) and wt mice (115 fold, table 1). We were curious to know 
the phenotype of mice deficient in both molecules. Therefore meningitis was induced in 
TLR2-/-/CD14-/- mice. Interestingly, survival was similar to that observed in either TLR2-/- 
or CD14-/- mice and the double KO animals were rescued with antibiotics alone (figure 
5). To understand the observations we measured increase of bacterial load in brain and 
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leukocyte infiltration in CSF. In these mice, unlike in TLR2-/- mice, early bacterial 
clearance was unimpaired (figure 6A) and cfu increased only 84 fold after 12 hours (table 
1). Leukocyte immigration was neither delayed as in TLR2-/- nor accelerated as in CD14-/- 
mice (figure 6B, table 1). Following the modest increase in cfu and leukocytes, TNF rose 
only 27 fold in the double KO mice (table 1). This indicates that the lack of TLR2 and 
CD14 in vivo was compensated by other receptors or that the opposite effects of TLR2 
and CD14 were neutralized.  
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Discussion 
 
 We compared treatment effects of antibiotics and TACE inhibitor TNF484 in 
mice during pneumococcal meningitis; in particular we studied differential modulation of 
the treatment response by the pattern recognition receptors TLR2 and CD14, either singly 
or combined. By simultaneous study of 4 mouse strains, we confirmed our earlier data 
that wt mice with untreated S. pneumoniae meningitis lived longer than infected mice 
with a genetic deletion of TLR2, CD14 or both receptors. We found, first, that antibiotics, 
which rescued wt and CD14-/- mice, were insufficient in the TLR2-/- strain; combination 
with TACE inhibitor was required for rescue in that group. Second, TACE inhibitor 
TNF484 therapy alone delayed death in TLR2-/- and CD14-/- but did not significantly 
improve in wt mice. Third, untreated and antibiotic-treated TLR2-/-/CD14-/- mice behaved 
similarly as single CD14-/- mice. 
 In meningitis, the timing of antibiotic treatment is an essential variable 
determining outcome, early therapy was associated with a lower mortality than late 
therapy (27). This is most likely due to the fact, that antibiotics are less efficient, as soon 
as the deleterious inflammation, which follows accumulation of bacteria, has developed. 
In our study the bacterial load and consequently the extent of inflammation may also 
have decided on the antibiotic response of the different mouse strains. Indeed in wt mice, 
we found a 100% response in lethal meningitis with 103 cfu of S. pneumoniae, when 
cephalosporin was applied parenterally 18 h after infection. At that time, bacterial 
numbers in CSF and brains were similar in wt and CD14-/- mice, but significantly higher 
in brains of TLR2-/- mice. The different status of the disease in TLR2-/- as compared to the 
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other mice was further documented by the clinical picture; 24 h after infection, 50% of 
TLR2-/- mice showed clinical symptoms of meningitis, whereas in wt and CD14-/- mice, 
only a small proportion of mice had symptoms (20 and 10%, respectively). Therefore it is 
likely, that the bacteria could be cleared by antibiotics in wt and CD14-/- , but not in 
TLR2-/- mice.  
 The inability of TLR2-/- mice to clear S. pneumoniae as fast as wt and CD14-/- 
mice, was followed by a stronger inflammation, which was recorded as higher TNF level 
in CSF from infected TLR2-/- as compared to CD14-/- and to wt mice. Accordingly the 
treatment of choice in TLR2-/- mice was an anti-inflammatory adjunctive drug. Based on 
our earlier studies with TACE inhibitor TNF484 in neonatal rat pneumococcal 
meningitis, we first confirmed that TACE inhibitor TNF484 used at 1 mg/kg twice daily 
blocked TNF in CSF of infected mice. The therapeutic effect was weak in wt, which at 
the time, when treatment was started, had a low TNF in CSF; it was significant in 
receptor-deficient mice, in which TNF release was higher after 24 h. So the profit from 
treatment in TLR2-/- and CD14-/- mice could be predicted from the TNF levels, which 
indicated a higher degree of inflammation than in wt mice.  
 Since TLR2-/- mice were rescued by neither antibiotics nor TACE inhibitors 
alone, combined treatment was applied and resulted in 80% survival in this mouse strain. 
It can be hypothetized, that TACE treatment was also effective, because it reduced the 
inflammation induced by cell wall active antibiotics, such as ceftriaxone (29). However, 
in vitro penicillin treatment of S. pneumoniae was found to induce host inflammation in a 
TLR2-dependent manner, since it led to IL-8 promoter activation in TLR2-transfected 
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cells (30). This finding suggests that antibiotic treatment did not augment inflammation 
in TLR2-/- mice.  
 So far, the in vivo consequences of a double TLR2/CD14 deletion in mice are 
unknown. The association of CD14 with TLR2 in a heteromeric complex was shown to 
be required for cell activation by TLR2 ligands (31). The evidence comes from the fact 
that cotransfection of CD14 with TLR2 increased peptidoglycan-induced reporter gene 
activation (11). Furthermore the association of CD14 and TLR2 was demonstrated by 
coimmunoprecipitation of TLR2 and CD14 in double transfected cells (32). It is however 
unknown, whether all TLR2-positive cells coexpress CD14 and whether for all signals 
CD14 is upstream TLR2. It is also unclear whether TLR2 is activated via ligand-loaden 
sCD14 in cells, which lack membrane CD14. Schwandner et al. showed that 
peptidoglycan-induced activation of TLR2 in transfected cells was stronger in the 
absence than in the presence of serum, which indicates that sCD14 may not act like 
membrane CD14 in the activation of TLR2 (11). Based on the in vitro findings the 
phenotype of infected double KO mice was not predictable.  
 Also, we had observed different phenotypes in TLR2-/- and CD14-/- mice during 
meningitis, which suggested that certain effects were dependent on both receptor and 
others not. We knew that TLR2 deficiency alone caused a very early delay of bacterial 
clearance, while CD14 did not affect early bacterial clearance (9, 24) (and table 1 this 
paper). Interestingly, double KO mice behaved like CD14-/- mice, they had a similar or 
better bacterial clearance and no change in leukocyte infiltration (table 1). Double KO 
died earlier than wt mice, but could be rescued with antibiotics like wt and CD14-/- mice. 
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This means that the lack of CD14 with its ensuing early infiltration compensated for the 
defect in bacterial killing of the TLR2-deficiency.  
 
Our treatment study reveals the different effects mediated by TLR2 and CD14 
respectively in meningitis and illustrates the requirement and success of adjuvant therapy, 
when bacterial load is high and inflammation is strong in TLR2-/-mice.  
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Figure 1. A, Effect of antibiotic treatment on mortality of wt (without ceftriaxone, solid 
line (n = 33); with ceftriaxone, thick solid line (n = 15); P < .001) and TLR2-/- mice (without 
ceftriaxone, dashed line (n = 21); with ceftriaxone, thick dashed line (n = 15); P < .001).  
B, Effect of antibiotic treatment on mortality of wt (without ceftriaxone, solid line (n = 33); with 
ceftriaxone, thick solid line (n = 15); P < .001) and CD14-/- mice (without ceftriaxone, dashed line 
(n = 21); with ceftriaxone, thick dashed line (n = 9); P < .001) in pneumococcal meningitis. 
Arrows indicate start of twice daily therapy with 80 mg/kg ceftriaxone i.p. 
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Figure 2. TNF release in CSF during pneumococcal meningitis in wt, TLR2-/- and CD14-/- 
mice. Values at 24 h (mean values; 329.4 pg/mL, 1077 pg/mL and 613.4 pg/mL in wt, TLR2-/- 
and CD14-/- mice, respectively) and 48 h (mean values; 48.4 pg/mL, 600.9 pg/mL and 300 pg/mL 
in wt, TLR2-/- and CD14-/- mice, respectively) after infection were compared by ANOVA 
repeated measures. Values at both time points were significantly (P < .05) different between wt, 
TLR2-/- and CD14-/- mice.  
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Figure 3. Effect of TACE inhibitor treatment on outcome of pneumococcal meningitis in 
wt, TLR2-/- and CD14-/- mice. A, Survival rate in wt (without TNF484, solid line (n = 25); with 
TNF484, thick solid line (n = 25), P > .05) and TLR2-/- mice (without TNF484, dashed line (n = 
25); with TNF484, thick dashed line (n = 25), P < .05; wt vs TLR2-/- treated, P > .05). B, Survival 
rate in wt (without TNF484, solid line (n = 20); with TNF484, thick solid line (n = 12), P > .05) 
and CD14-/- mice (without TNF484, dashed line (n = 12); with TNF484, thick dashed line (n = 
12), P < .05; wt vs CD14-/- treated, P > .05). Arrows indicate start of twice daily therapy with 1 
mg/kg TNF484 s.c. 
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Figure 4. Effect of antibiotic and TACE inhibitor treatment on outcome of pneumococcal 
meningitis in wt and TLR2-/- mice.  
Survival rate in wt (without treatment, solid line (n = 10); with treatment, thick solid line (n = 10), 
P < .001) and TLR2-/- mice (without treatment, dashed line (n = 10); with treatment, thick dashed 
line (n = 10), P < .001); wt vs TLR2-/- treated, P > .05). 
Arrows indicate start of therapy with 1 mg/kg TNF484 s.c. and 80 mg/kg ceftriaxone i.p. twice 
daily, starting 12 h and 18 h after infection, respectively. 
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Figure 5. Survival of wt (___) mice was significantly longer than survival of TLR2-/- (_ _ _), 
CD14-/- (
_ _ _
), and TLR2-/-/CD14-/- (
…
) mice during pneumococcal meningitis. Survival in the 
three deficient strains did not differ. Antibiotic treatment rescued all TLR2-/-/CD14-/- (
…
) mice.  
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Figure 6. Colony-forming units (cfu) in brain and leukocyte numbers in CSF in 4 mouse 
strains early during meningitis. A, Fold increase of brain cfu between 6 and 12 h after infection in 
wt, TLR2-/-, CD14-/- and TLR2-/-/CD14-/- mice; values are average of 4 mice. B, Leukocyte 
numbers in CSF 6 and 12 h after infection (values are average of 4 mice, * P < .05). 
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 Table.   Fold increase in brain bacterial numbers, leukocyte counts and TNF in  
CSF during pneumococcal meningitis. 
Mouse strain Fold increase cfu a Fold increase 
leukocytes in CSF a
Fold increase 
TNF in CSF b
CD14+/TLR2+ 220 10 115 
CD14+/TLR2-/- 442 2 408 
CD14-/-/TLR2+ 134 22 333 
CD14-/-/TLR2-/- 84 15 27 
NOTE.    a Fold increase between 6 and 12 h after S. pneumoniae infection. 
    b Fold increase between 12 and 24 h after S. pneumoniae infection. 
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Future perspectives 
 Despite highly active antibiotics and the development of capsular polysaccharide 
vaccines, bacterial meningitis is still associated with high morbidity and mortality in both 
children and adults. Streptococcus pneumoniae remains the major cause of acute bacterial 
meningitis in adults in developed countries [1]. Standard anti-microbial drugs, which are 
administered orally, may not achieve therapeutic concentrations in the subarachnoid 
space, since the penetration of an antibiotic into cerebrospinal fluid is primarily 
influenced by characteristics of the antibiotic and the integrity of the blood-brain barrier 
[2]. Vancomycin, which represents an effective treatment for S. pneumoniae meningitis 
in the era of ß-lactam resistance, has limited penetration into the CSF [3]. In addition, 
antibiotic therapy of suspected bacterial meningitis is usually given empirically, which 
may not be efficient in the presence of multi-drug-resistant pneumococci. Moreover, 
effective antimicrobial drugs, such as ß-lactam antibiotics, can induce the release of 
lipoteichoic acid (LTA) and teichoic acid (TA) from S. pneumoniae [4], which may 
contribute to an unfavorable outcome [5]. Indeed LTA and TA have been shown to 
induce severe meningeal inflammation when injected into the subarachnoid space of 
rabbits [6] and their concentrations in CSF were significantly associated with 
neurological sequelae and mortality in patients with pneumococcal meningitis [7]. 
However, the release of proinflammatory components, such as LTA and TA, occurs also 
during spontaneous bacterial lysis. 
 Our increasing understanding of the pathogenesis and the host response in 
bacterial meningitis has suggested new approaches to modulate host immune activation. 
Indeed, the inflammation within the subarachnoid space and neuronal damage, which 
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occur during bacterial meningitis, are not mediated simply by the presence of live 
bacteria but occur as a consequence of the host’s inflammatory response to bacterial 
components [8]. Indeed, experimental studies have clearly demonstrated that 
pneumococcal cell wall components induce CSF inflammation [5] and cellular damage in 
primary astrocyte and microglial cell cultures from newborn rats [9]. It was further shown 
that LTA, peptidoglycans and pneumococcal DNA were capable of damaging neurons 
and glia in organotypic hippocampal cultures [10]. Therefore, in order to prevent or 
attenuate harmful subarachnoid space inflammation and neurological damage, additional 
therapies, which can modulate the host immune system response to pneumococci have 
been considered.  
 Corticosteroids were then used as anti-inflammatory adjuvant in the treatment of 
bacterial meningitis [11]. In 1997, a meta-analysis of all randomized clinical trials of 
dexamethasone as adjunctive therapy in bacterial meningitis from 1988 to 1996 
concluded that dexamethasone treatment has beneficial effects on patients with 
Haemophilus influenza type b meningitis and children with pneumococcal meningitis 
when the treatment was started with or before parenteral antibiotics [12]. Recently, a 
prospective, randomized, double-blind European trial of adjuvant treatment with 
dexamethasone in 301 adults with acute bacterial meningitis showed that early steroid use 
(before or with the first dose of antibiotic) is associated with improved survival and 
outcome [13]. In this study, among the patients with pneumococcal meningitis, there 
were unfavorable outcomes in 26% of the dexamethasone group, as compared with 52% 
of the group which received placebo. The dexamethasone treatment did not increase the 
incidence of severe neurological disability or the risk of gastrointestinal bleeding [13]. A 
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recent meta-analysis of adjunctive steroid therapy in five trials, involving 623 adults with 
acute bacterial meningitis (pneumococcal meningitis = 234, meningococcal meningitis = 
232, others = 127, unknown = 30) showed that treatment with dexamethasone was 
associated with a significant reduction in mortality and in neurological sequelae in 
pneumococcal meningitis [14]. In this study, subgroup analysis for patients with 
meningococcal and other bacterial meningitis also showed a favorable trend in mortality 
and neurological sequelae in the absence of any excess adverse events. However, there is 
one caveat to these beneficial effects of dexamethasone in experimental model of 
pneumococcal meningitis [15]. The authors showed that dexamethasone treatment 
increased hippocampal apoptosis and reduced learning capacity in pneumococcal 
meningitis in infant rats. 
 Bacterial meningitis is characterized by neutrophil accumulation into the CSF. 
Therefore, another approach was used to attenuate PMN recruitment in the subarachnoid 
space and thus prevent meningeal inflammation. It was shown that inhibition of 
leukocyte recruitment into the CSF by blocking ß2-integrins with anti-CD18 antibody 
markedly reduced meningeal inflammation in a rabbit model of pneumococcal meningitis 
[16]. Other studies have used similar approach with the polysaccharide fucoidin, which is 
a selectin blocker that inhibits leukocyte rolling and subsequent leukocyte 
transendothelial migration [17]. Treatment with fucoidin intravenously has been found to 
attenuate pleocytosis and reduce inflammatory parameters, such as intracranial pressure 
in experimental pneumococcal meningitis in rats [18]. However, in this study, rats were 
intracisternally injected with pneumococcal cell wall components instead of live bacteria, 
which does not represent a real experimental meningitis model. In a recent study, 
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fucoidin was used in rabbits intracisternally injected with live serotype 3 S. pneumoniae 
strain [19]. In this study, fucoidin treatment prevented CSF pleocytosis and thus inhibited 
the release of proinflammatory cytokines into the CSF such as IL-1ß. 
Cytokines modulate chemokine expression, i.e MIP-2 is found higher in IL-6-/- mice than 
in wt mice after intracisternal pneumococcal infection [20] and chemokines themselves 
are causative of the pleocytosis, since it has been shown that anti-MIP-2 antibodies 
reduced leukocyte infiltration. 
 In addition to cytokines and chemokines, matrix metalloproteins, which 
contribute to the integrity of the BBB are found increased in patients with meningitis 
[20]. Accordingly, treatment with matrix metalloproteinases inhibitors reduced CSF TNF, 
BBB permeability and the extent of neuronal injury in infant rat model of pneumococcal 
meningitis [21] [22]. 
 
The approach in our study was to understand the mechanisms of cellular activation 
triggered by the bacteria-host immune cells interactions in an experimental model of 
pneumococcal meningitis. We therefore investigated the in vivo role of two specific 
pattern recognition receptors, TLR2 and CD14, which mediate cellular activation towards 
Gram-positive cell wall components. The function of these two receptors has been 
intensively studied in vitro in response to heat killed pneumococci or pneumococcal cell 
wall components but no in vivo study using experiemental model of bacterial meningitis 
was reported. We were the first to investigate the in vivo function of TLR2 in 
experimental pneumococcal meningitis model using TLR2-/- mice [23]. We could show 
that TLR2-deficiency was associated with reduced pneumococcal clearance from the 
 144
central nervous system (CNS), increased meningeal inflammation and BBB permeability, 
and earlier death due to pneumococcal meningitis. These results demonstrated the 
importance of TLR2 in the induction of protective innate immunity to pneumococcal 
infection. TLR2 most likely modulates inflammatory response induced by S. pneumoniae 
or its cell wall components, thus preventing harmful meningeal inflammation, which 
leads to brain damage. This observation was further confirmed by the fact that antibiotic 
treatment could not rescued all TLR2-/- mice (27% died), since these mice showed a 
strong meningeal inflammation at the time of treatment. TLR2 is not only involved in the 
modulation of TNF response in the subarachnoid space but plays a major role in 
mediating phagocytosis and/or killing of S. pneumoniae, as shown by a greater bacterial 
load in the CNS of TLR2-/- mice as compared to wt mice [23]. Indeed, it was recently 
observed that in TLR2-/- macrophages infected with Staphylococcus aureus, phagosomes 
showed deficient fusion with lysosomes, which are crucial for bacterial killing [24]. 
 In the second paper, which is submitted, we investigated the in vivo role of CD14 
in the pathogenesis of pneumococcal meningitis. CD14 binds Gram-positive cell wall 
components [25] [26] [27] but requires interaction with TLR2 to initiate signal 
transduction in response to Gram-positive bacteria [28]. However, the pathophysiologic 
role of CD14 in Gram-positive bacterial infection is still unknown. In our study, CD14 
deficiency was associated with early strong PMN recruitment into the subarachnoid 
space, which leads to increased meningeal inflammation. This strong CSF pleocytosis 
was due to more MIP-2 release in brain. Moreover, brain endothelial cells from CD14-/- 
mice, in vitro infected with live S. pneumoniae released more MIP-2 than those from wt 
mice. In contrast to TLR2, CD14 does not play any role in bacterial clearance, but is 
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rather involved in controlling PMN recruitment into the CSF, and thus prevents harmful 
and deleterious meningeal inflammation. This is a new function of a pattern recognition 
receptor to modulate PMN migration in pneumococcal infection. It will be interesting to 
understand the mechanisms by which CD14 interferes with MIP-2 release.  
 In the third paper, which is also submitted, we were mainly interested in the 
modulation of TLR2 and CD14-mediated cellular functions by antibiotic and TACE 
inhibitor treatment in pneumococcal meningitis. We could show that both wt and CD14-/- 
mice were rescued with ceftriaxone therapy, whereas TLR2-/- mice required additional 
anti-inflammatory drug (TACE inhibitor) to be cured. These results could be explained 
by an excessive CSF inflammation observed in TLR2-/- mice as compared to wt or CD14-
/- mice. Therefore we investigated the course of meningitis and the treatment response of 
TLR2-/-/CD14-/- mice. It appears that TLR2-/-/CD14-/- mice behaved like CD14-/- mice. 
Indeed all TLR2-/-/CD14-/- mice could be rescued by ceftriaxone therapy. This suggests 
that early lack in bacterial clearance, which was characteristic for TLR2-/- mice was 
somehow compensated by early leukocyte infiltration (characteristic for CD14-/- mice).  
 
Taken all together, our data showed that although both TLR2 and CD14 recognize Gram-
positive cell wall components in vitro, their in vivo functions towards live Gram-positive 
bacteria are completely different. Our findings show a direct implication of TLR2 and 
CD14 in the host response towards S. pneumoniae and contribute to a better 
understanding of the host innate immunity in the experimental pneumococcal meningitis 
model.  
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Besides vaccination, which remains a priority in populations who are at risk, such as 
elderly and patients who are immunocompromised, we believe that our studies help 
understanding modulation of the innate immune response to pneumococci and thus to 
design adjunctive therapies which are promising in reducing CSF inflammation and 
neurological sequelae and thus improve outcome in pneumococcal meningitis. 
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